sbbp_Current Folio_6K

0001558370-17-006055.txt : 20170807 0001558370-17-006055.hdr.sgml : 20170807 20170807080716 ACCESSION NUMBER: 0001558370-17-006055 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170807 DATE AS OF CHANGE: 20170807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Strongbridge Biopharma plc CENTRAL INDEX KEY: 0001634432 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981130690 STATE OF INCORPORATION: L2 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37569 FILM NUMBER: 171010113 BUSINESS ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 BUSINESS PHONE: (610) 254-9200 MAIL ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 FORMER COMPANY: FORMER CONFORMED NAME: Cortendo AB DATE OF NAME CHANGE: 20150219 6-K 1 sbbp-20170630x6k.htm 6-K sbbp_Current Folio_6K_10Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of August 2017

Commission file number 001-37569

Strongbridge Biopharma plc

(Exact name of Registrant as specified in its charter)

900 Northbrook Drive

Suite 200

Trevose, PA 19053

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Introduction

As used herein, “Strongbridge Biopharma”, the “Company” and “we”, “our” or “us” refer to Strongbridge Biopharma plc and its consolidated subsidiaries, unless the context requires otherwise.

Strongbridge Biopharma plc’s unaudited consolidated financial statements contained in this Report on Form 6-K are presented in United States dollars (“$”) and are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 6-K contains forward‑looking statements that involve substantial risks and uncertainties. The forward‑looking statements are contained principally in the sections of this Current Report on Form 6-K titled “Business,” “Update to Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All statements, other than statements of historical facts, contained in this Current Report on Form 6-K, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, size of market or patient population, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products, are forward‑looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward‑looking statements. Forward-looking statements can be identified by words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “positioned,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or other similar expressions, although not all forward‑looking statements contain these identifying words. Forward‑looking statements are based on our current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions. They are not guarantees of future results, performance or developments and are subject to known and unknown risks, uncertainties and other factors. Factors that may cause our actual results or developments to differ materially from the expectations contained in the forward-looking statements include, but are not limited to:

our ability to successfully commercialize Keveyis® (dichlorphenamide) and any other product candidates we receive approval for;

the timing, progress and results of clinical and preclinical trials for our product candidates;

our ability to obtain and maintain regulatory approval for our product candidates;

our ability to secure additional financing when needed on acceptable terms;

our ability to effectively manage our anticipated growth;

our ability to develop our commercial organization and recruit and retain qualified sales representatives;

our ability to successfully implement our business model, as well as strategic plans for our business, product candidates and technology;

our ability to implement and execute our business strategy to in‑license, acquire and develop new product candidates;

our ability to retain our key personnel and our ability to recruit, retain and motivate additional qualified personnel;

our ability to develop and maintain relationships with manufacturers, clinical research organizations and other important contractors and consultants;

potential product liability claims and our ability to obtain adequate insurance;

our ability to expand, protect and enforce our intellectual property rights;

our ability to obtain and maintain orphan drug exclusivity for Keveyis or our product candidates;

the impact of government laws and regulations in the United States and foreign countries;

Actual results could differ materially from the plans, intentions and expectations disclosed in the forward‑looking statements we make. As a result, any or all of our forward‑looking statements in this Current Report on Form 6-K may turn out to be inaccurate. We have included important factors in the cautionary statements included in this Current Report on Form 6-K, particularly in the section of this Current Report on Form 6-K titled “Update to Risk Factors,” that we believe could cause actual results or events to differ materially from the forward‑looking statements that we make. We may not actually achieve the plans, intentions or expectations disclosed in our forward‑looking statements, and you should not place undue reliance on our forward‑looking statements. Moreover, we operate in a highly competitive and rapidly changing environment in which new risks often emerge. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward‑looking statements we may make. Our forward‑looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. Any forward-looking statement made by us in this report is based only on information currently available to us and speaks only as of the date of this report. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made by us, from time to time, whether as a result of new information, future developments or otherwise.

Business

We are a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

Our first commercial product is Keveyis® (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration (“FDA”) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (“PPP”). Keveyis has orphan drug exclusivity status in the United States through August 7, 2022. Since acquiring the U.S. marketing rights for Keveyis in December 2016, we have hired key management personnel responsible for the build out of sales, marketing, market access and patient service capabilities. We have also hired 12 highly-experienced, rare disease field force personnel. We believe, based on our market research, that there are approximately 4,000 to 5,000 patients in the United States diagnosed with PPP. In April 2017, we launched and recorded our initial sales of Keveyis.

In addition to this neuromuscular disease product, we have two clinical-stage product candidates for rare endocrine diseases, Recorlev™ and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both Recorlev and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency (“EMA”).

Given the well-identified and concentrated prescriber base addressing our target markets, we intend to use a small, focused sales force to effectively market Keveyis and our other products and product candidates, if approved, in the United States, the European Union and other key global markets. We believe that our ability to execute on this strategy is enhanced by the significant commercial and clinical development experience of key members of our management team. We will continue to identify and evaluate the potential acquisition of other products and product candidates that would be complementary to our existing rare neuromuscular and endocrine franchises or that would form

the basis for new rare disease franchises. We believe this approach will enable us to maximize our commercial potential by further leveraging our existing resources and expertise.

Recent Developments

On July 14, 2017, we entered into a $50 million senior credit facility with CRG LP (“CRG”), a healthcare-focused investment firm, to retire our prior credit facility with Oxford Finance LLC and Horizon Technology Finance Corporation and provide additional capital to us. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. We intend to use the equity proceeds and the remainder of the initial loan proceeds (after deducting loan origination costs and other fees and expenses incurred in connection with the incurrence of the loan), plus any additional amounts that may be borrowed in the future, for general corporate purposes and working capital.

The term loan agreement has a six-year term with three years of interest-only payments. The interest-only period may be extended to six years based upon the achievement of certain milestones during the first three years of the loan term. As a condition to the new credit facility, we issued warrants with a seven-year term to CRG to purchase 394,289 of our ordinary shares at an exercise price of $7.37 per share.

Update to Risk Factors

We have a limited operating history on which to assess our business, have incurred significant losses over the last several years, and anticipate that we will continue to incur losses until achieving sufficient revenues from Keveyis and one or more of our product candidates.

Until we acquired the U.S. marketing rights to Keveyis®, in December 2016, we were a development-stage biopharmaceutical company. We have a limited operating history and have not yet demonstrated an ability to successfully complete a large-scale, pivotal clinical trial, obtain regulatory approval, or manufacture and commercialize a product candidate. Other than our limited commercial experience with Keveyis, we have no meaningful prior commercial operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.

Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, in-licensing or acquiring our product candidates, identifying potential product candidates, undertaking preclinical studies and clinical trials of our product candidates, and launching Keveyis in April 2017. During the first half of 2017, we established our initial sales force and marketing and distribution capabilities, and we plan to continue expand this commercial infrastructure. To achieve commercial success of Keveyis and any product candidates that are approved, we will have to expand our sales, marketing and supply capabilities or outsource these activities to a third party.

Since inception, we have incurred significant operating losses. Our net loss was $59.7 million for the six months ended June 30, 2017. As of June 30, 2017, we had an accumulated deficit of $189.1 million. We have devoted substantially all of our financial resources to identifying, in-licensing, acquiring and developing our product candidates, including conducting clinical trials, commercializing Keveyis (since December 2016), and providing general and administrative support for these operations.

To date, we have financed our operations primarily through private placements of equity securities, the proceeds from our initial public offering of ordinary shares in the United States in October 2015, and debt financings. The amount of our future net losses will depend, in part, on whether we successfully commercialize Keveyis and the rate of our future expenditures as well as our ability to obtain funding through strategic collaborations or grants. To become and remain profitable, we must successfully commercialize Keveyis and develop and eventually commercialize one or more of our product candidates with significant market potential.

We have never been, and may never be, profitable.

We have only one product, Keveyis®, approved for commercialization, and two product candidates in development. We will not generate significant revenue from product sales unless we launch Keveyis successfully or until we successfully complete the development of, obtain regulatory approval for and commercialize one or more of our product candidates. Our ability to generate significant future revenue from product sales and become profitable depends heavily on our success in many areas, including, but not limited to:

integrating Keveyis and any other products or product candidates that we in-license or acquire, as well as completing research, formulation and process development, and preclinical or clinical development, as applicable, of those product candidates, including successfully completing clinical trials of those product candidates;

obtaining regulatory approval of our product candidates;

maintaining supply and manufacturing relationships with third parties that can conduct the manufacturing process development and provide adequate, in amount and quality, products to support clinical development and the market demand for Keveyis® and any other product candidates, if approved;

obtaining market acceptance of Keveyis and our product candidates, if approved, as viable treatment options, and persuading adequate numbers of physicians to prescribe Keveyis and other product candidates, if approved;

addressing any competing technological and market developments;

identifying, assessing, in‑licensing, acquiring and/or developing new product candidates;

negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;

maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know‑how; and

attracting, hiring and retaining adequate numbers of qualified sales and marketing personnel.

We are currently advancing two product candidates through clinical development, Recorlev (levoketoconazole and formerly called COR-003) and veldoreotide (formerly called COR-005). Development of product candidates is expensive, and we expect our research and development expenses to increase in connection with our ongoing activities, particularly as we continue our ongoing trials and initiate new nonclinical studies and clinical trials of Recorlev, veldoreotide and any other product candidates we may seek to develop.

Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. It may be several years, if ever, before we receive regulatory approval and have a product candidate, other than Keveyis, approved for commercialization. Our future revenue from Keveyis and from any other product candidates approved for commercialization will depend upon the size of the markets in which our product candidates are marketed, or in which they may receive approval, and our ability to achieve market acceptance and adequate market share for our product candidates in those markets.

Given the numerous risks and uncertainties associated with pharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. We expect to continue to incur significant expenses and operating losses until we successfully commercialize Keveyis and one or more of our product candidates. We anticipate that our expenses will increase substantially if and as we:

establish a sales, marketing and distribution infrastructure to commercialize Keveyis and any other products for which we may obtain regulatory approval;

continue research and nonclinical and clinical development of our product candidates, including advancing our programs from preclinical development into clinical trials and increasing the number and size of our current clinical trials and preclinical studies;

make up‑front, milestone or other payments under any asset acquisition, supply, or license arrangements;

seek to identify, assess, in‑license, acquire and develop additional product candidates;

change or add manufacturers or suppliers;

seek regulatory approvals for our product candidates that successfully complete clinical trials;

seek to maintain, protect and expand our intellectual property portfolio;

seek to attract and retain skilled personnel;

create additional infrastructure to support our operations as a U.S. listed company and our product development and planned future commercialization efforts; and

experience any delays or encounter issues with any of the above, including, but not limited to, failed preclinical studies or clinical trials, complex results, safety issues or other regulatory challenges that may require either longer follow‑up of existing preclinical studies or clinical trials or limitation of additional preclinical studies or clinical trials in order to pursue regulatory approval.

Further, the net losses we incur may fluctuate significantly from quarter‑to‑quarter and year‑to‑year, such that a period‑to‑period comparison of our results of operations may not be a good indication of our future performance. Moreover, if we incur substantial losses, we could be liquidated, and the value of our shares might be significantly reduced or the shares might be of no value.

We have incurred, and anticipate we will continue to incur, significant costs associated with commercializing Keveyis, as well as any other product candidates that are approved. Further, our revenue will be dependent, in part, upon the size of the markets in the territories for which we have received regulatory approval, the accepted price for the product, the ability to obtain coverage and adequate reimbursement, and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of our product candidates. If we are not able to generate sufficient revenue from the sale of any approved products, we may never become profitable. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to successfully execute any of the foregoing would decrease the value of our company and could impair our ability to raise capital, expand our business or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment.

The terms of our credit facility place restrictions on our operating and financial flexibility.

The Loan Agreement with CRG includes affirmative and negative covenants applicable to us and any subsidiaries we create in the future. The affirmative covenants include, among others, covenants requiring us to maintain our legal existence and governmental approvals necessary for us and our subsidiaries to perform our respective businesses and obligations under the Loan Agreement, deliver certain financial reports to the Lenders, maintain insurance coverage, and comply with certain financial covenants. The negative covenants include, among others, restrictions on our transferring collateral, changing our business, engaging in mergers or acquisitions, incurring

additional indebtedness, paying dividends or making other distributions, making investments, creating liens, or entering into transactions with affiliates, in each case subject to certain exceptions.

The Loan Agreement also includes events of default, the occurrence and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 4.0% and would provide the lenders holding more than 50% of the aggregate commitments under the credit facilities, and CRG, as collateral agent, with the right to exercise remedies against us and the collateral securing the credit facility, including foreclosure against our assets securing the credit facilities, including our cash. These events of default include, among others, our failure to pay any amounts due under the Loan Agreement, a breach of covenants under the Loan Agreement, a material adverse change, our insolvency, the occurrence of a default under any material agreement with a third party, and/or one or more judgments are rendered against us or our subsidiaries in an amount greater than $250,000 individually or in the aggregate.

Our ability to make scheduled payments on or to refinance our indebtedness depends on our future performance and ability to raise additional sources of cash, which is subject to economic, financial, competitive and other factors beyond our control. If we are unable to generate sufficient cash to service our debt, we may be required to adopt one or more alternatives, such as selling assets, restructuring our debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. If we desire to refinance our indebtedness, our ability to do so will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.

We will cease to qualify as a foreign private issuer in 2018, which will require us to comply with the Exchange Act’s domestic reporting regime and NASDAQ’s requirements for domestic issuers and may cause us to incur increased legal, accounting and other expenses.

We are a foreign private issuer and have not been required to comply with the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. As of the end of our second fiscal quarter in 2017, however, we have determined that we will no longer satisfy the eligibility requirements of a foreign private issuer, and will lose our status as a foreign private issuer beginning in 2018. As a result, in 2018 we will be required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers, and will no longer be eligible for certain exemptions from NASDAQ’s corporate governance requirements. The Exchange Act’s disclosure and reporting requirements for domestic issuers are generally more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices to comply with SEC and stock exchange rules. The costs for us to comply with these regulatory requirements may be significantly higher than the costs we have generally incurred as a foreign private issuer. Further, we may become subject to procedural requirements, including NASDAQ rules requiring shareholder approval for certain types of equity offerings, that may impede our ability to conduct certain types of financings or otherwise delay our ability to take corporate actions. We also expect that complying with the rules and regulations applicable to a domestic issuer may make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.

STRONGBRIDGE BIOPHARMA plc

Consolidated Balance Sheets

(In thousands, except share and per share data)

(unaudited)


	June 30,		December 31,
	2017		2016
ASSETS
Current assets:
Cash and cash equivalents	$	33,864	$	66,837
Accounts receivable		616		—
Inventory		1,403		—
Prepaid expenses and other current assets		1,863		764
Total current assets		37,746		67,601
Property and equipment, net		20		25
Deferred tax asset		—		1,599
Intangible assets, net		58,389		60,900
Goodwill		7,256		7,256
Other assets		301		150
Total assets	$	103,712	$	137,531
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,200	$	1,089
Accrued liabilities		6,958		14,868
Total current liabilities		8,158		15,957
Long-term debt		18,566		18,434
Warrant liability		41,237		11,090
Supply agreement liability, noncurrent		25,921		25,078
Total liabilities		93,882		70,559
Commitments and contingencies (Note 8)
Stockholders’ equity:
Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at June 30, 2017 and December 31, 2016		44		44
Ordinary shares, $0.01 par value, 600,000,000 shares authorized at June 30, 2017 and December 31, 2016; 35,335,026 shares issued and outstanding at June 30, 2017 and December 31, 2016		353		353
Additional paid-in capital		198,508		195,975
Accumulated deficit		(189,075)		(129,400)
Total stockholders’ equity		9,830		66,972
Total liabilities and stockholders’ equity	$	103,712	$	137,531

The accompanying notes are an integral part of these unaudited consolidated financial statements.

STRONGBRIDGE BIOPHARMA plc

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(unaudited)


	Three Months Ended				Six Months Ended
	June 30				June 30
	2017		2016		2017		2016
Revenues:
Net product sales	$	1,529	$	—	$	1,529	$	—
Total revenues		1,529		—		1,529		—

Cost and expenses:
Cost of sales (excluding amortization of intangible asset)	$	377	$	—	$	377	$	—
Research and development		4,128		4,572		7,609		11,366
Selling, general and administrative		10,142		4,014		17,584		8,143
Amortization of intangible asset		1,255		—		2,511		—
Impairment of intangible asset		—		5,228		—		5,228
Total cost and expenses		15,902		13,814		28,081		24,737
Operating loss		(14,373)		(13,814)		(26,552)		(24,737)
Other income (expense), net:
Unrealized loss on fair value of warrants		(15,219)		—		(30,147)		—
Interest expense		(737)		—		(1,474)		—
Foreign exchange (loss) gain		(14)		3		(25)		(44)
Other income (expense), net		60		44		25		(1,246)
Total other income (expense), net		(15,910)		47		(31,621)		(1,290)
Loss before income taxes		(30,283)		(13,767)		(58,173)		(26,027)
Income tax (expense) benefit		92		871		(1,502)		926
Net loss		(30,191)		(12,896)		(59,675)		(25,101)
Net loss attributable to non-controlling interest		—		55		—		105
Net loss attributable to Strongbridge Biopharma	$	(30,191)	$	(12,841)	$	(59,675)	$	(24,996)

Net loss attributable to ordinary shareholders:
Basic and diluted	$	(30,191)	$	(12,841)	$	(59,675)	$	(24,996)
Net loss per share attributable to ordinary shareholders:
Basic and diluted	$	(0.86)	$	(0.61)	$	(1.69)	$	(1.18)
Weighted-average shares used in computing net loss per share attributable to ordinary shareholders:
Basic and diluted		35,335,026		21,205,382		35,335,026		21,205,382

The accompanying notes are an integral part of these unaudited consolidated financial statements.

STRONGBRIDGE BIOPHARMA plc

Consolidated Statement of Shareholders’ Equity

(In thousands except share amounts)

(unaudited)


							Additional				Total
	Ordinary Shares			Deferred Shares			Paid-In		Accumulated		Shareholders’
	Shares	Amount		Shares	Amount		Capital		Deficit		Equity
Balance—December 31, 2016	35,335,026	$	353	40,000	$	44	$	195,975	$	(129,400)	$	66,972
Net loss	—		—	—		—		—		(59,675)		(59,675)
Stock-based compensation	—		—	—		—		2,533		—		2,533
Balance—June 30, 2017	35,335,026	$	353	40,000	$	44	$	198,508	$	(189,075)	$	9,830

The accompanying notes are an integral part of these unaudited consolidated financial statements.

STRONGBRIDGE BIOPHARMA plc

Consolidated Statements of Cash Flow

(In thousands)

(unaudited)


	Six Months Ended
	June 30,
	2017		2016
Cash flows from operating activities:
Net loss	$	(59,675)	$	(25,101)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability		30,147		—
Stock-based compensation		2,533		2,418
Amortization of intangible asset		2,511		—
Amortization of debt discounts and debt issuance costs		282		—
Deferred income tax expense (benefit)		1,599		(926)
Depreciation		5		5
Impairment of intangible asset		—		5,228
Impairment/loss on investment in Antisense Therapeutics		—		550
Changes in operating assets and liabilities:
Accounts receivable		(616)		—
Inventory		(1,403)		—
Prepaid expenses and other current assets		(1,099)		(95)
Other assets		(151)		825
Accounts payable		111		(827)
Accrued liabilities and other liabilities		433		184
Net cash used in operating activities		(25,323)		(17,739)
Cash flows from investing activities:
Payments for acquisition		(7,500)		—
Net cash used in investing activities		(7,500)		—
Cash flows from financing activities:
Payment for amendment of long-term debt		(150)		—
Net cash used in financing activities		(150)		—
Net decrease in cash and cash equivalents		(32,973)		(17,739)
Cash and cash equivalents—beginning of period		66,837		51,623
Cash and cash equivalents—end of period	$	33,864	$	33,884
Supplemental disclosures of cash flow information
Cash paid during the year for:
Income taxes other, net of refunds	$	255	$	—
Interest	$	762	$	—

The accompanying notes are an integral part of these unaudited consolidated financial statements.

STRONGBRIDGE BIOPHARMA plc

Notes to Unaudited Consolidated Financial Statements

1. Organization

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Our first commercial product is Keveyis® (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration ("FDA") for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Keveyis has orphan drug exclusivity status in the United States through August 7, 2022. In addition to this neuromuscular disease product, we have two clinical-stage product candidates for rare endocrine diseases, Recorlev™ and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both Recorlev and veldoreotide have received orphan designation from the FDA and the European Medicines Agency ("EMA").

Liquidity

As of June 30, 2017, we held cash and cash equivalents of $33.9 million. On July 14, 2017, we entered into a $50 million senior credit facility to retire our prior credit facility and provide us with additional capital. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. We intend to use the equity proceeds and the remainder of the initial loan proceeds (after deducting loan origination costs and other fees and expenses incurred in connection with the incurrence of the loan), plus any additional amounts that may be borrowed in the future, for general corporate purposes and working capital.

We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We believe the combination of our existing cash resources as of June 30, 2017 and the net proceeds from our July 14, 2017 debt and equity financing provides us with sufficient resources under our current operating plan, which includes the potential regulatory approval and launch of Recorlev, to achieve consistent positive cash flows from operating activities. We expect our funding requirements for operating activities to increase in 2017 and possibly beyond due to expenses associated with the commercialization of Keveyis, the execution of the Recorlev SONICS and LOGICS Phase 3 clinical trials, and our selling, general and administrative expenses. Our funding requirements will also increase to the extent we pursue potential in-licenses, acquisitions or similar transactions as part of our strategy. These expenses may be offset only in part by sales of Keveyis. To the extent our sales of Keveyis are less than we anticipate, or our expenses are higher than we anticipate, we may be required to fund our operations and capital needs through equity or debt financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us.

Our loan and security agreement contains financial and non-financial covenants including minimum amounts of net revenue in 2017 and beyond. Failure to comply with the covenants could result in the lenders declaring the loan immediately due and payable. Our liquidity requirements are predicated on maintaining compliance with the debt covenants and repaying outstanding borrowings in accordance with the loan agreement.

2. Summary of significant accounting policies and basis of presentation

Basis of presentation

These unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (U.S. GAAP). The unaudited consolidated financial statements reflect all adjustments, which include only normal recurring adjustments that are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented.

The preparation of the unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the consolidated financial statements. Actual results could differ from those estimates.

These unaudited consolidated financial statements should be read in conjunction with the accounting policies and notes to the audited consolidated financial statements included in Strongbridge Biopharma’s 2016 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2017. Operating results for the six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.

Revenue recognition

Prior to the April 2017 launch of Keveyis, we have not previously generated any revenue. Therefore, we adopted Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, effective April 1, 2017. Topic 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We apply the five-step model to contracts only when it is probable that we will collect the consideration we are entitled to receive in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for net product revenue, see Note 3, "Revenue Recognition".

Inventory

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Our inventory consists of only finished goods.

Foreign currency translation

The consolidated financial statements are reported in United States dollars, which is our functional currency, including each of our consolidated subsidiaries. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange gain (loss) in our consolidated statements of operations.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. We must apply significant judgment in this process. Actual results could materially differ from those estimates.

Net loss per share

Basic net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of shares of ordinary shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted‑average number of shares of ordinary shares outstanding for the period, including any dilutive effect from outstanding stock options or other equity-based awards. Shares used in the diluted net loss per share calculations exclude anti‑dilutive ordinary shares equivalents, which currently consist of outstanding stock options, unvested restricted stock units and warrants.

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of June 30, 2017 and 2016, as they would be anti-dilutive:


	Six Months Ended
	June 30,
	2017		2016
Warrants		7,428,571		—
Stock options issued and outstanding		6,139,647		3,293,341
Unvested restricted stock units		222,000		170,000

Recent accounting pronouncements

In January 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-04, Intangibles - Goodwill and Other: Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This standard, which will be effective for the us beginning in the first quarter of fiscal year 2021, is required to be applied prospectively. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact this standard will have on its financial statements.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows in order to reduce diversity in practice. The guidance is effective for us beginning in the first quarter of fiscal year 2018. Early adoption is permitted. We are currently evaluating the impact of adopting this guidance on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Improvements to Employee Share-Based Payment Accounting, which affects all entities that issue share-based payment awards to their employees. The amendments in this ASU cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess tax benefits on the statement of cash flows, an accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification and the classification of those taxes paid on the statement of cash flows. This ASU is effective for annual and interim periods beginning after December 15, 2016. This guidance can be applied either prospectively, retrospectively or using a modified retrospective transition method. Early adoption is permitted. We have adopted the standard effective January 1, 2017 and have elected to account for forfeitures as they occur as opposed to estimating forfeitures. The adoption of this standard did not have a material impact on our financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that discusses how an entity should account for lease assets and lease liabilities. The guidance specifies that an entity who is a lessee under lease agreements should recognize lease assets and lease liabilities for those leases classified as operating leases under previous FASB guidance. Accounting for leases by lessors is largely unchanged under the new guidance. The guidance is effective for the us beginning in the first quarter of fiscal year 2019. Early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements.

In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, that modifies certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The accounting standard update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption is permitted. We are currently assessing the impact that adopting this new accounting guidance will have on our consolidated financial statements.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU No. 2015-11 applies only to inventory for which cost is determined by methods other than last in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. We adopted this standard on April 1, 2017. The adoption of this standard had no impact on the Company’s consolidated financial statements, there was no accounting impact to previously issued financial statements based on our adoption.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. We adopted this new standard on April 1, 2017 in conjunction with the launch of Keveyis. As we did not record revenue prior to the quarter ending June 30, 2017, there was no accounting impact to previously issued financial statements based on our adoption of ASC Topic 606.

3. Revenue recognition

Product Revenue, Net

We sell Keveyis to one specialty pharmacy provider, (the “Customer”), who is the exclusive distributor of the Product in the United States. The Customer subsequently resells the Product to patients, which are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of the Product.

Revenues from sales of Keveyis are recognized when we satisfy a performance obligation by transferring control of Keveyis to the Customer. Transfer of control occurs upon receipt of Keveyis by the Customer. We expense incremental costs related to the set-up of the contract with the Customer when incurred as these costs did not meet the criteria for capitalization.

Reserves for Variable Consideration

consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We will reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known.

Trade Discount: We provide our Customer with a discount that is explicitly stated in our contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from our Customer. To the extent, the services received are distinct from our sale of products to the Customer, these payments are classified in selling, general and administrative expenses in our consolidated statement of operations and comprehensive loss.

Funded Co-pay Assistance Program: We contract with a third-party to manage the co-pay assistance program intended to provide financial assistance to qualified insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with Product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. These payments are consideration payable to the customer and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet.

Government Rebates: We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated patient mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. Effective January 1, 2011, manufacturers of pharmaceutical products are responsible for 50% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this Medicare coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for the Product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.

Temporary Supply and Patient Assistance Programs: We provide free Product to uninsured patients who satisfy pre-established criteria for either the Temporary Supply Program or the Patient Assistance Program. Patients who meet the Temporary Supply Program eligibility criteria may receive a temporary supply of free Product for no more than sixty days while we are determining the patient’s third-party insurance, prescription drug benefit or other third-party coverage for the Product. The Patient Assistance Program provides free Product for up to twelve months to patients that satisfy pre-established criteria for financial need. We do not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in our consolidated statements of operations and comprehensive loss.

To date, our only source of product revenue has been from the U.S. sales of the Product, which we began shipping to the Customer in April 2017. The following table summarizes activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2017 (in thousands):



				Co-pay
		Trade		assistance		Government
		discount		program		rebates		Total
Balance at December 31, 2016	$	—	$	—	$	—	$	—
Provision related to current period sales		72		42		159		273
Adjustment related to prior period sales		—		—		—		—
Credit or payments made during the period		(72)		(35)		—		(107)
Balance at June 30, 2017	$	—	$	7	$	159	$	166

4. Fair value measurement

We follow FASB accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. Because of their short term nature, the amounts reported in the balance sheet for cash and cash equivalents, and accounts payable approximate fair value.

The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Because of their short term nature, the amounts reported in the balance sheet for cash and cash equivalents, and accounts payable approximate fair value.

Level 2: Significant observable inputs other than Level 1 prices such as quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The fair values of the outstanding warrants were measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement.

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):


	As of June 30, 2017
	Level I		Level II		Level III		Total
Cash equivalents		33,579		—		—		33,579
Total assets	$	33,579	$	—	$	—	$	33,579
Warrant liabilities		—		—		41,237		41,237
Total liabilities	$	—	$	—	$	41,237	$	41,237


	As of December 31, 2016
	Level I		Level II		Level III		Total
Warrant liabilities		—		—		11,090		11,090
Total liabilities	$	—	$	—	$	11,090	$	11,090

5. Intangible assets and goodwill

The gross carrying amount of in‑process research and development, acquired developed product rights and goodwill is as follows (in thousands):


	As of June 30, 2017
	Beginning of Period		Additions		Amortization		End of Period
IPR&D	$	20,723	$	—	$	—	$	20,723
Acquired product rights		40,177		—		(2,511)		37,666
Goodwill		7,256		—		—		7,256
Total	$	68,156	$	—	$	(2,511)	$	65,645


	As of December 31, 2016
	Beginning of Period		Additions		Impairment		End of Period
IPR&D	$	36,551	$	—	$	(15,828)	$	20,723
Acquired product rights		—		40,177		—		40,177
Goodwill		7,256		—		—		7,256
Total	$	43,807	$	40,177	$	(15,828)	$	68,156

Our finite lived intangible asset consists of acquired developed product rights obtained from the asset acquisition of Keveyis® (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (“Taro”). Keveyis is approved in the United States to treat hyperkalemic, hypokalemic and related variants of primary periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. Keveyis has received orphan drug exclusivity status in the United States through August 7, 2022. In connection with the Asset Purchase Agreement and Supply Agreement we entered into with Taro, we have paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017. We concluded that the supply price payable by us exceeds fair value and, therefore, used a discounted cash flow method with a probability assumption to value the payments in excess of fair value at $29.3 million, for which we have recorded an intangible asset and corresponding liability. This liability will be reduced as we purchase inventory over the term of the Supply Agreement. In addition, we incurred transaction costs of $2.4 million, which were recorded in our Statement of Operations during the year ended December

31, 2016. The overall recording of the transaction resulted in the recording of an intangible asset of $40.2 million. This asset is being amortized over an eight-year period using the straight-line method.

We recorded amortization expense of $2.5 million and $0 for the six months ended June 30, 2017 and 2016, respectively.

6. Accrued liabilities

Accrued liabilities consist of the following (in thousands):


	June 30,		December 31,
	2017		2016
Consulting and professional fees	$	2,573	$	1,110
Accrued payable due Taro Pharmaceuticals Industries Ltd.		—		7,500
Accrued interest		430		—
Supply agreement - current portion		2,574		4,207
Employee compensation		1,351		1,554
Other		30		497
Total accrued liabilities	$	6,958	$	14,868

7. Long-Term debt

On December 28, 2016, we entered into a loan and security agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Horizon Technology Finance Corporation (“Horizon”) (collectively, the “Lenders”). The Loan Agreement provided for a $40 million credit facility, of which $20 million was borrowed initially. Under the Loan Agreement, we have access to two additional tranches of $10 million each, which would be available to us, subject to the achievement of certain specified milestones.

The borrowings pursuant to the Loan Agreement mature after 48 months. The Loan Agreement provides for interest-only payments initially for the first 18 months of the loan followed by an amortization period of 30 months, a final payment fee equal to 8% of the amount borrowed, and interest payable at an annual rate equal to the sum of 8.22% plus the greater of 0.53% or the 30-day US LIBOR rate. The credit facility provides that if we satisfy certain milestones and borrows the final $10 million tranche, the interest-only period would be extended by an additional six months and the amortization period would be 24 months. We have granted a security interest in substantially all of its existing assets and assets acquired by us in the future, including intellectual property. The Loan Agreement contains facility and prepayment fees, and customary affirmative and negative covenants, including a financial covenant regarding minimum amounts of net revenue and events of default and restricts the payment of cash dividends. The Loan Agreement contains a material adverse change clause whereby a material adverse change in our business, operations or financial condition would be considered an event of default whereby the lenders could declare all amounts under the Loan Agreement as immediately due and payable. We incurred $1.3 million in debt discounts and $0.3 million of debt issuance costs relating to this Loan Agreement, each of which have been recorded as a reduction to the long-term debt. These amounts will be amortized over the outstanding period of the debt to interest expense using the effective interest rate method.

In connection with the execution of the Loan Agreement, we issued warrants to the Lenders to purchase an aggregate of 428,571 ordinary shares at an exercise price equal to $2.45 per share. The warrants were immediately exercisable and expire after ten years. We accounted for these warrants as equity, and the fair value was recorded into additional paid-in capital.

On March 31, 2017, we entered into an amendment to the Loan Agreement that was made effective as of January 27, 2017 and provided for an extension to the dates by which our Swedish subsidiary was required to enter into security documents granting security interests on certain of its assets in favor of Oxford, as collateral agent for the Lender, and to increase the amount of debt we can incur under, and the amount of cash collateral it can provide for purposes of, our corporate credit card program from $100,000 to $250,000. In connection with the amendment, we paid

$150,000 to the Lenders. The $150,000 was recorded as additional debt discount cost and will be amortized as an adjustment of interest expense over the remaining term of the Loan.

Future principal payments due under the Loan Agreement are as follows (in thousands):


	Principal
	Payments

2017	$	—
2018		4,000
2019		8,000
2020		8,000
Total future payments	$	20,000

On June 22, 2017, we notified the Lenders of our intentions to prepay our current Loan Agreement. Effective July 14, 2017 we retired the Loan Agreement and incurred a prepayment fee of $0.8 million and final payment interest charge of $1.6 million.

8. Commitments and contingencies

(a) Lease obligations

In March 2015, we entered into a 52‑month building sublease agreement for 14,743 square feet of office space in Trevose, Pennsylvania. The lease has annual rent escalations and is recognized on a straight‑line basis over the term of the lease.

As of June 30, 2017, future minimum commitments under facility operating leases were as follows (in thousands):


	Operating
	leases

2017	$	159
2018		319
2019		184
Total minimum lease payments	$	662

Rent expense recognized under our operating lease, including additional rent charges for utilities, parking, maintenance and real estate taxes, was approximately $152,000 and $138,000 for the six months ended June 30, 2017 and 2016, respectively.

(b) Commitments to Taro Pharmaceuticals Industries Ltd.

In December 2016, we acquired the United States marketing rights to Keveyis® (dichlorphenamide) from a subsidiary of Taro. Keveyis is approved in the United States to treat hyperkalemic, hypokalemic and related variants of primary periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. Keveyis has received orphan drug exclusivity status in the United States through August 7, 2022. Under the terms of an asset purchase agreement, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017, and will pay an aggregate of $7.5 million in potential milestones upon the achievement of certain product sales targets. Taro has agreed to continue to manufacture Keveyis for us under an exclusive supply agreement through the orphan exclusivity period. We are obligated to purchase certain annual minimum amounts of product totaling approximately $29 million over a six-year period. The supply agreement may extend beyond the orphan exclusivity period unless terminated by either party pursuant to the terms of the agreement. If terminated by Taro at the

conclusion of the orphan exclusivity period, we have the right to manufacture the product on our own or have the product manufactured by a third party on our behalf.

9. Income taxes

Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized.

We assess our ability to realize deferred tax assets. Changes in future earnings projections, among other factors, may cause us to adjust our valuation allowance on deferred tax assets. Any such adjustments would impact our income tax expense in the period in which it is determined that these factors have changed.

For the six months ended June 30, 2017, we recorded a full valuation allowance against our deferred tax asset, resulting in income tax expense of $1.5 million.

10. Stock‑based compensation

Our board of directors has adopted, the 2017 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of equity-based awards to new employees. The purpose of the Inducement Plan is to attract valued employees by offering them a greater stake in our success and a closer identity with us, and to encourage ownership of our ordinary shares by such employees. The Inducement Plan is effective as of February 23, 2017. As of June 30, 2017, 89,850 shares are available for issuance pursuant to the Inducement Plan.

Our board of directors has adopted, and our shareholders have approved, the 2015 Equity Compensation Plan (the “2015 Plan”). The 2015 Plan provides for the grant of incentive stock options to our employees and any parent or subsidiary corporations’ employees, and for the grant of nonstatutory stock options, stock awards, and restricted stock units to our employees, directors and consultants and our parent or subsidiary corporations’ employees and consultants. The 2015 Plan is effective as of September 3, 2015. As of June 30, 2017, 428,814 shares are available for issuance pursuant to the 2015 Plan.

Our board of directors has adopted, and our shareholders have approved, the Non‑Employee Director Equity Compensation Plan (the “Non‑Employee Director Plan”). The Non‑Employee Director Plan provides for the grant of nonstatutory stock options, stock awards, and restricted stock units to our non‑employee directors. The Non‑Employee Director Plan is effective as of September 3, 2015. As of June 30, 2017, 792 shares are available for issuance pursuant to the Non‑Employee Director Plan.

A summary of our outstanding stock options as of June 30, 2017 is as follows:


	Options Outstanding
				Weighted-
				Average
		Weighted-		Remaining
		Average		Contractual
	Number of	Exercise		Term	Aggregate
	Shares	Price		(Years)	Intrinsic Value
					(in thousands)
Outstanding—January 1, 2017	3,249,784	$	11.00	6.89	$	—
Granted	2,943,200	$	3.44
Forfeited and cancelled	(53,337)	$	8.28
Exercised	—		—
Outstanding—June 30, 2017	6,139,647	$	7.40	8.02	$	14,417
Vested and exercisable—June 30, 2017	1,758,858	$	10.63	5.68	$	1,924

Included in the stock options outstanding at June 30, 2017 are unvested stock options to purchase 88,908 shares at a weighted average exercise price of $18.80 per share for which the vesting of certain tranches will accelerate if the fair value per share of our stock reaches $31.46. In addition, the options outstanding include 97,652 shares that vest upon a market appreciation event, so long as it occurs prior to May 26, 2019 and 97,652 shares that will vest upon the one year anniversary of the market appreciation event. The market appreciation event, which had not yet occurred as of June 30, 2017, is defined as the last trading day in the period in which our closing stock price on each of 20 consecutive trading days reported on NASDAQ has been at least $30.14 or $33.66 for the respective grantee.

Stock‑based compensation expense

We recognized stock‑based compensation expense for employees and directors for stock options and RSUs in the accompanying unaudited consolidated statements of operations as follows (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016
Research and development	$	281	$	(87)	$	498	$	196
General and administrative		1,082		1,177		2,035		2,222
Total stock-based compensation	$	1,363	$	1,090	$	2,533	$	2,418

As of June 30, 2017, the total unrecognized compensation expense related to unvested stock options, net of estimated forfeitures, is $11.3 million, which we expect to recognize over an estimated weighted‑average period of 2.92 years.

In determining the estimated fair value of our service-based awards, we use the Black‑Scholes option‑pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.

The fair value of our service-based awards that were granted during the years was estimated with the following assumptions:


	Six Months Ended
	June 30,
	2017	2016
Expected term (in years)	5.95	5.87
Risk-free interest rate	1.78% - 2.26%	1.3% - 1.6%
Expected volatility	78.2% - 81.8%	78.1% - 83.6%
Dividend rate	—%	—%

Restricted Stock Units

On February 26, 2016, our board of directors approved grants of restricted stock units (“RSUs”) to employees. These RSUs vest two years from the date of issuance, provided that the employee is employed by us on such vesting date. All RSUs will fully vest upon a change of control of our company. If and when the RSUs vest, we will issue one ordinary share for each whole RSU that has vested, subject to satisfaction of the executive’s tax withholding obligations. The RSUs will cease to be outstanding upon such issuance of ordinary shares. We recorded expense, which is included in the stock-based compensation table above, of $98,000 and $78,000 for the three months ended June 30, 2017 and 2016, respectively, and $185,000 and $112,000 for the six months ended June 30, 2017 and 2016, respectively. As of June 30, 2017, the total unrecognized compensation expense related to unvested RSUs is $0.4 million, which we expect to recognize over an estimated weighted‑average period of 1.2 years.

A summary of our unvested RSUs as of June 30, 2017 is as follows:


		Number of
		Shares
Unvested—January 1, 2017		184,000
Granted		40,000
Forfeited		(2,000)
Vested		—
Unvested—June 30, 2017		222,000

11. Subsequent Events

On July 14, 2017, we entered into a $50 million senior credit facility with CRG LP (“CRG”), a healthcare-focused investment firm, to retire our existing debt facility and provide additional capital to us. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with this first tranche, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. The term loan agreement has a six-year term with three years of interest-only payments. The interest-only period may be extended to six years based upon the achievement of certain milestones during the first three years of the loan term. As a condition to the new credit facility, we issued warrants with a seven-year term to CRG to purchase 394,289 ordinary shares at an exercise price of $7.37 per share. In addition, pursuant to terms of the new credit facility, we used a portion of the initial loan proceeds to repay all of the amounts we owed under the Loan Agreement to Oxford and Horizon, and the other lenders named therein. We intend to use the remainder of the initial loan proceeds (after deducting loan origination costs and other fees and expenses incurred in connection with the incurrence of the loan), plus any additional amounts that may be borrowed in the future, for general corporate purposes and working capital.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion summarizes the significant factors affecting our operating results, financial condition, liquidity and cash flows as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the unaudited financial statements for the six months ended June 30, 2017 and the related notes thereto included elsewhere in this Current Report on 6-K. The statements in this discussion regarding industry outlook, our expectations regarding our future performance, liquidity and capital resources and all other non‑historical statements in this discussion are forward‑looking statements and are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward‑looking statements as a result of various factors, including those discussed below and elsewhere in this Current Report on 6-K.

Overview

We are a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

Our first commercial product is Keveyis® (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration (“FDA”) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (“PPP”), a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. Keveyis has orphan drug exclusivity status in the United States through August 7, 2022. We believe, based on our market research, that there are approximately 4,000 to 5,000 patients in the United States diagnosed with PPP.

In addition to this neuromuscular disease product, we have two clinical-stage product candidates for rare endocrine diseases, Recorlev™ and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog (“SSA”) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both Recorlev and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency (“EMA”).

We have never been profitable and have incurred net losses since our inception in 1996. Our operations to date have been focused on identifying, in‑licensing, acquiring and developing our product candidates, organizing and staffing our company, business planning and raising capital. We have funded our operations primarily through equity offerings. We incurred a net loss attributable to Strongbridge Biopharma plc of $59.7 million and $25.0 million for the six months ended June 30, 2017 and 2016, respectively. At June 30, 2017, our accumulated deficit was $189.1 million.

Financial Operations Overview

The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.

Net Revenue

We sell Keveyis to one specialty pharmacy provider, (the “Customer”), who is the exclusive distributor of Keveyis in the United States. The Customer subsequently resells Keveyis to patients, which are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of the Keveyis.

We recognize revenues from sales of Keveyis when we satisfy a performance obligation by transferring control of Keveyis to the Customer. Transfer of control occurs upon receipt of Keveyis by the Customer. We expense incremental costs related to the set-up of the contract with the Customer when incurred as these costs did not meet the criteria for capitalization.

Cost of Sales

Cost of sales includes third-party acquisition costs, third-party warehousing and product distribution charges.

Research and Development Expenses

Our research and development expenses consist primarily of costs incurred in connection with the development of our product candidates, including:

personnel‑related costs, such as salaries, bonuses, benefits, travel and other related expenses, including stock‑based compensation;

expenses incurred under our agreements with contract research organizations (“CROs”), clinical sites, contract laboratories, medical institutions and consultants that plan and conduct our preclinical studies and clinical trials, including, in the case of consultants, stock‑based compensation;

costs associated with regulatory filings;

upfront and milestone payments under in‑license or acquisition agreements with third parties;

costs of acquiring preclinical study and clinical trial materials, and costs associated with formulation and process development; and

depreciation, maintenance and other facility‑related expenses.

We expense all research and development costs as incurred. Clinical development expenses for our product candidates are a significant component of our current research and development expenses as we progress our product candidates into and through clinical trials. Product candidates in later stage clinical development generally have higher research and development costs than those in earlier stages of development, primarily due to increased size and duration of the clinical trials. We recognize costs for each grant project, preclinical study or clinical trial that we conduct based on our evaluation of the progress to completion, using information and data provided to us by our external research and development vendors and clinical sites.

We expect our research and development expenses to increase in absolute dollars in the future as we continue to in‑license or acquire product candidates and as we advance our existing and any future product candidates into and through clinical trials and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical research to obtain regulatory approval of a product candidate is costly and time consuming. The probability that any of our product candidates receives regulatory approval and eventually is able to generate revenue depends on a variety of factors, including the quality of our product candidates, early clinical data, investment in our clinical program, competition, manufacturing capability and commercial viability. As a result of these uncertainties, we are unable to determine the duration and completion costs of our research and development projects or if, when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates, if approved. We may never succeed in achieving regulatory approval for any of our product candidates.

We do not allocate personnel‑related research and development costs, including stock‑based compensation or other indirect costs, to specific programs, as they are deployed across multiple projects under development.

Selling, General and Administrative Expenses

Selling, general and administrative expenses include personnel costs, costs for outside professional services and other allocated expenses. Personnel costs consist of salaries, bonuses, benefits, travel and stock‑based compensation. Outside professional services consist of legal, accounting and audit services, commercial evaluation and strategy services, sales, marketing and other consulting services. We expect to incur additional selling, general and administrative costs as a result of our initial and on-going commercial activities in support of our Keveyis product.

Amortization of Intangible Asset

Amortization of intangible asset relates to the amortization of our product rights to Keveyis, which we acquired in December of 2016. This intangible asset is being amortized over an eight-year period using the straight-line method.

Other Income (Expense), Net

Other income (expense), net, consists of unrealized (loss)/gain on the remeasurement of the fair value of warrant liability, interest expense recognized on our long-term debt, interest income generated from our cash and cash equivalents, foreign exchange gains and losses and gains and losses on investments.

Our consolidated financial statements are reported in U.S. dollars, which is also our functional currency. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign currency gain (loss) in other income (expense) in our consolidated statements of operations.

Critical Accounting Policies and Significant Judgments and Estimates

This management’s discussion and analysis operating and financial review of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

In addition to our critical accounting policies described in the “Operating and Financial Review and Prospects” section included in our Annual Report on Form 20-F for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission on April 4, 2017, we have adopted our Revenue Recognition policy. See Note 3 – Revenue Recognition.

Results of Operations

Comparison of the Three and Six Months Ended June 30, 2017 and 2016

The following table sets forth our results of operations for the three and six months ended June 30, 2017 and 2016.


	Three Months Ended						Six Months Ended
	June 30,				Change		June 30,				Change
	2017		2016		$		2017		2016		$
	(in thousands)						(in thousands)
Revenues:
Net product sales	$	1,529	$	—	$	1,529	$	1,529	$	—	$	1,529
Total revenues		1,529		—		1,529		1,529		—		1,529

Cost and operating expenses:
Cost of sales (excluding amortization of intangible asset)	$	377	$	—	$	377	$	377	$	—	$	377
Research and development		4,128		4,572		(444)		7,609		11,366		(3,757)
Selling, general and administrative		10,142		4,014		6,128		17,584		8,143		9,441
Amortization of intangible asset		1,255		—		1,255		2,511		—		2,511
Impairment of intangible asset		—		5,228		(5,228)		—		5,228		(5,228)
Total cost and expenses		15,902		13,814		2,088		28,081		24,737		3,344
Operating loss		(14,373)		(13,814)		(559)		(26,552)		(24,737)		(1,815)
Other income (expense), net		(15,910)		47		(15,957)		(31,621)		(1,290)		(30,331)
Loss before income taxes		(30,283)		(13,767)		(16,516)		(58,173)		(26,027)		(32,146)
Income tax (expense) benefit		92		871		(779)		(1,502)		926		(2,428)
Net loss		(30,191)		(12,896)		(17,295)		(59,675)		(25,101)		(34,574)
Net loss attributable to non‑controlling interest		—		55		(55)		—		105		(105)
Net loss attributable to Strongbridge	$	(30,191)	$	(12,841)	$	(17,350)	$	(59,675)	$	(24,996)	$	(34,679)

Net Revenue and Cost of Sales.

Net revenue of $1.5 million and cost of sales of $0.4 million for the three and six months ended June 30, 2017 resulted from our initial commercial sales of Keveyis following our product launch in April 2017.

Amortization of Intangible Asset

Amortization of intangible asset increased by $1.3 million and $2.5 million for the three and six months ended June 30, 2017 compared to $0 for the three and six months ended June 30, 2016, as we begin amortizing the Keveyis product rights acquired in December, 2016.

Research and Development Expenses

The following table summarizes our research and development expenses during the three and six months ended June 30, 2017 and 2016:


	Three Months Ended						Six Months Ended
	June 30,				Change		June 30,				Change
	2017		2016		$		2017		2016		$
	(in thousands)						(in thousands)
Product development and supporting activities	$	2,959	$	3,925	$	(966)	$	5,445	$	9,375	$	(3,930)
Compensation and other personnel costs		888		734		154		1,666		1,795		(129)
Stock-based compensation expense		281		(87)		368		498		196		302
Total research and development expenses	$	4,128	$	4,572	$	(444)	$	7,609	$	11,366	$	(3,757)

Research and development expenses were $4.1 million for the three months ended June 30, 2017, a decrease of $0.4 million compared to the three months ended June 30, 2016. The $1.0 million decrease in expenses for product development and supporting activities was primarily due to a $0.4 million decrease in expenses relating to the ongoing clinical trials for Recorlev, a $0.3 million decrease in development expenses related to programs we discontinued during 2016 (COR-004 and BioPancreate), and a $0.3 million decrease in expenses for veldoreotide development activity. Compensation and other personnel costs increased by $0.2 million for the three months ended June 30, 2017 as compared to the same period in 2016 due to increased headcount in research and development. Stock-based compensation expense increased by $0.4 million, for the three months ended June 30, 2017 as compared to the same period in 2016 due to the granting of new awards to newly hired employees during the 2017 period.

Research and development expenses were $7.6 million for the six months ended June 30, 2017, a decrease of $3.8 million compared to the six months ended June 30, 2016. The $3.9 million decrease in expenses for product development and supporting activities was primarily due to a $1.5 million decrease in development expenses related to programs we discontinued during 2016 (COR-004 and BioPancreate), a $1.3 million decrease in expenses for veldoreotide development activity, and a $1.1 million decrease in expenses relating to the ongoing clinical trials for Recorlev. Compensation and other personnel costs decreased by $0.1 million for the six months ended June 30, 2017 compared to the same period in 2016. Stock-based compensation expense increased by $0.3 million, for the six months ended June 30, 2017 as compared to the same period in 2016 due to the granting of new awards to newly hired employees during the 2017 period.

Selling, General and Administrative Expenses

The following table summarizes our selling, general and administrative expenses during the three and six months ended June 30, 2017 and 2016:


	Three Months Ended						Six Months Ended
	June 30,				Change		June 30,				Change
	2017		2016		$		2017		2016		$
	(in thousands)						(in thousands)
Outside professional and consulting services	$	5,038	$	1,561	$	3,477	$	9,539	$	3,237	$	6,302
Compensation and other personnel costs		3,925		1,188		2,737		5,827		2,509		3,318
Stock-based compensation expense		1,082		1,177		(95)		2,035		2,222		(187)
Facility costs		97		88		9		183		175		8
Total general and administrative expenses	$	10,142	$	4,014	$	6,128	$	17,584	$	8,143	$	9,441

Selling, general and administrative expenses were $10.1 million for the three months ended June 30, 2017, an increase of $6.1 million compared to the three months ended June 30, 2016. The $3.5 million increase in outside professional and consulting services was primarily due to costs incurred for the launch and subsequent

commercialization of Keveyis. Compensation and related personnel costs increased by $2.7 million during the three months ended June 30, 2017 due to increased headcount of commercial personnel.

Selling, general and administrative expenses were $17.6 million for the six months ended June 30, 2017, an increase of $9.4 million compared to the six months ended June 30, 2016. The $6.3 million increase in outside professional and consulting services was primarily due to costs incurred for the launch and subsequent commercialization of Keveyis. Compensation and related personnel costs increased by $3.3 million during the six months ended June 30, 2017 due to increased headcount of commercial personnel.

Other Income (Expense), Net

The following table summarizes our other expense, net, during the six months ended June 30, 2017 and 2016:


	Three Months Ended						Six Months Ended
	June 30,				Change		June 30,				Change
	2017		2016		$		2017		2016		$
	(in thousands)						(in thousands)
Unrealized loss on fair value of warrants	$	(15,219)	$	—	$	(15,219)	$	(30,147)	$	—	$	(30,147)
Interest expense		(737)		—		(737)		(1,474)		—		(1,474)
Foreign exchange loss		(14)		3		(17)		(25)		(44)		19
Other income (expense), net		60		44		16		25		(1,246)		1,271
Total other income (expense), net	$	(15,910)	$	47	$	(15,957)	$	(31,621)	$	(1,290)	$	(30,331)

Other expense, net, increased by $16.0 million for the three months ended June 30, 2017 as compared to the three months ended June 30, 2016. The increase was primarily due to a $15.2 million change in the fair value of our warrant liability, primarily resulting from an increase in our stock price, and $0.7 million in interest expense.

Other expense, net, increased by $30.3 million for the six months ended June 30, 2017 as compared to the six months ended June 30, 2016. The increase was primarily due to a $30.1 million change in the fair value of our warrant liability, mostly resulting from an increase in our stock price, and $1.5 million in interest expense. Other expense, net decreased by $1.3 million, due to a one-time $1.1 million charge incurred in March 2016 relating to the termination of our license agreement with Antisense Therapeutics.

Income Tax

We recorded income tax expense of $1.5 million for the six months ended June 30, 2017 as a result of recording a valuation allowance against our deferred tax asset, and a benefit of $0.9 million for the six months ended June 30, 2016 due to impairment of intangible assets held by a since-dissolved subsidiary.

Cash Flows

Comparison for the Six Months Ended June 30, 2017 and 2016


	Six Months Ended
	June 30
	2017		2016
	(in thousands)
Net cash used in by:
Operating activities	$	(25,323)	$	(17,739)
Investing activities		(7,500)		—
Financing activities		(150)		—
Net decrease in cash and cash equivalents	$	(32,973)	$	(17,739)

Operating Activities

Net cash used in operating activities was $25.3 million for the six months ended June 30, 2017, compared to $17.7 million for the six months ended June 30, 2016. The increase in net cash used in operating activities resulted primarily from investments during 2017 to support the commercialization of Keveyis.

Investing Activities

The increase in net cash used in investing activities resulted from our scheduled payment of $7.5 million to Taro Pharmaceutical Industries Ltd in connection with our acquisition of the U.S. marketing rights of Keveyis.

Financing Activities

The increase in net cash used in financing activities resulted from a payment of $150,000 to our lenders, in connection with amending our long-term debt arrangement.

Liquidity

As of June 30, 2017, we held cash and cash equivalents of $33.9 million. On July 14, 2017, we entered into a $50 million senior credit facility to retire our prior debt facility and provide us with additional capital. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. We intend to use the equity proceeds and the remainder of the initial loan proceeds (after deducting loan origination costs and other fees and expenses incurred in connection with the incurrence of the loan), plus any additional amounts that may be borrowed in the future, for general corporate purposes and working capital.

We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We believe the combination of our existing cash resources as at June 30, 2017 and the net proceeds from our July 14, 2017 debt and equity financing provides us with sufficient resources under our current operating plan, which includes the potential regulatory approval and launch of Recorlev, to achieve consistent positive cash flows from operating activities. We expect our funding requirements for operating activities to increase in and possibly beyond due to expenses associated with the commercialization of Keveyis, the execution of the Recorlev SONICS and LOGICS Phase 3 clinical trials, and our selling, general and administrative expenses. Our funding requirements will also increase to the extent we pursue potential in-licenses, acquisitions or similar transactions as part of our strategy. These expenses may be offset only in part by sales of Keveyis. To the extent our sales of Keveyis are less than we anticipate, or our expenses are higher than we anticipate, we may be required to fund our operations and capital funding needs through equity or debt financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us.

Contractual Obligations and Other Commitments

The following table summarizes our future minimum commitments at June 30, 2017:


	Payments due by period
	Less than						More than
	1 year		1 to 3 years		3 to 5 years		5 years		Total
	(in thousands)

Minimum contract purchases pursuant to supply agreement	$	2,463	$	5,018	$	10,835	$	7,835	$	26,151
Debt payments	$	—	$	16,000	$	4,000	$	—	$	20,000
Operating leases	$	159	$	503	$	—	$	—	$	662
Total contractual obligations	$	2,622	$	21,521	$	14,835	$	7,835	$	46,813

In addition to the debt payment noted above, we entered into a new term loan in July 2017. This term loan agreement has a six-year term with three years of interest-only payments. The interest-only period may be extended to six years based upon the achievement of certain milestones during the first three years of the loan term.

We enter into agreements in the normal course of business with vendors for clinical trials, preclinical studies, and other services and products for operating purposes. Future payment obligations under these agreements, which are cancelable at any time by us, generally upon 30 days prior written notice, are not included in this table of contractual obligations.

We are obligated to make future payments to third parties due to payments that become due and payable upon the achievement certain commercialization milestones. As the amount and timing of these milestones are not probable and estimable, such commitments have not been included on our consolidated balance sheets or in the contractual obligations table above.

Off‑Balance Sheet Arrangements

We do not have variable interests in variable interest entities or any off‑balance sheet arrangements.

Quantitative and Qualitative Disclosures About Market Risk

At June 30, 2017, we had cash and cash equivalents of $33.9 million, which consists of bank deposits in the United States. As part of our cash and investment management processes, we perform periodic evaluations of the credit standing of the financial institutions with which we deposit our cash or purchase cash equivalents, and we have not sustained any credit losses from instruments held at these financial institutions.

Inflation

We believe the effects of inflation generally do not have a material adverse impact on our operations or financial condition.

Legal Proceedings

We are not party to any litigation or other legal proceedings that we believe could reasonably be expected to have a material adverse effect on our business, results of operations and financial condition.

EXHIBITS

EXHIBIT INDEX

10

10
101.INS*		XBRL Instance Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*		XBRL Taxonomy Extension Definitions Linkbase Document

* Filed herewith.

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Current Report on Form 6-K and that it has duly caused and authorized the undersigned to sign this report on its behalf.



	STRONGBRIDGE BIOPHARMA PLC

	By:		/s/ A. BRIAN DAVIS
	Name:		A. Brian Davis
	Title:		Chief Financial Officer

Date: August 7, 2017

EX-101.INS 2 sbbp-20170630.xml EX-101.INS 0001634432 sbbp:ProductRevenueAllowanceAndReserveMember 2017-06-30 0001634432 sbbp:ProductRevenueAllowanceAndReserveGovernmentRebatesMember 2017-06-30 0001634432 sbbp:ProductRevenueAllowanceAndReserveCoPayAssistanceProgramMember 2017-06-30 0001634432 us-gaap:SubsequentEventMember 2017-07-14 2017-07-14 0001634432 us-gaap:RetainedEarningsMember 2017-06-30 0001634432 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001634432 us-gaap:RetainedEarningsMember 2016-12-31 0001634432 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001634432 us-gaap:CommonStockMember 2017-06-30 0001634432 sbbp:DeferredSharesMember 2017-06-30 0001634432 us-gaap:CommonStockMember 2016-12-31 0001634432 sbbp:DeferredSharesMember 2016-12-31 0001634432 us-gaap:SubsequentEventMember 2017-07-14 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-06-30 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-06-30 0001634432 sbbp:VestingSubjectToAccelerationMember 2017-06-30 0001634432 sbbp:NonEmployeeDirectorEquityCompensationPlanMember 2017-06-30 0001634432 sbbp:InducementPlan2017Member 2017-06-30 0001634432 sbbp:EquityCompensationPlan2015Member 2017-06-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001634432 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0001634432 sbbp:TaroPharmaceuticalIndustriesMember sbbp:AcquiredDevelopedProductRightsMember sbbp:KeveyisMember sbbp:AssetPurchaseAgreementMember 2017-03-01 2017-03-31 0001634432 sbbp:TaroPharmaceuticalIndustriesMember sbbp:AcquiredDevelopedProductRightsMember sbbp:KeveyisMember sbbp:AssetPurchaseAgreementMember 2016-12-01 2016-12-31 0001634432 sbbp:CreditFacility2016Member 2017-03-31 2017-03-31 0001634432 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001634432 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001634432 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001634432 sbbp:LeaseArrangementMarch2015Member 2015-03-01 2015-03-31 0001634432 sbbp:CreditFacility2016Member 2017-07-14 2017-07-14 0001634432 us-gaap:InProcessResearchAndDevelopmentMember 2017-06-30 0001634432 us-gaap:InProcessResearchAndDevelopmentMember 2016-12-31 0001634432 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001634432 us-gaap:InProcessResearchAndDevelopmentMember 2016-01-01 2016-12-31 0001634432 sbbp:AcquiredDevelopedProductRightsMember 2016-12-01 2016-12-31 0001634432 sbbp:AcquiredDevelopedProductRightsMember 2017-06-30 0001634432 sbbp:TaroPharmaceuticalIndustriesMember sbbp:AcquiredDevelopedProductRightsMember sbbp:KeveyisMember sbbp:SupplyAgreementMember 2016-12-31 0001634432 sbbp:AcquiredDevelopedProductRightsMember 2016-01-01 2016-12-31 0001634432 sbbp:EmployeeAndDirectorsStockOptionsMember 2017-06-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0001634432 sbbp:EmployeeAndDirectorsStockOptionsMember 2017-01-01 2017-06-30 0001634432 sbbp:WarrantsIssuedLoanAgreementTwoMember us-gaap:SubsequentEventMember 2017-07-14 0001634432 sbbp:WarrantsIssuedLoanAgreementOneMember sbbp:CreditFacility2016Member 2016-12-28 0001634432 sbbp:CreditFacility2016Member us-gaap:MinimumMember 2017-03-31 0001634432 sbbp:CreditFacility2016Member us-gaap:MaximumMember 2017-03-31 0001634432 2016-06-30 0001634432 2015-12-31 0001634432 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001634432 us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001634432 sbbp:LeaseArrangementMarch2015Member 2015-03-31 0001634432 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0001634432 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-06-30 0001634432 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001634432 sbbp:AcquiredDevelopedProductRightsMember 2017-01-01 2017-06-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2017-04-01 2017-06-30 0001634432 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001634432 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0001634432 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001634432 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2016-04-01 2016-06-30 0001634432 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001634432 us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-06-30 0001634432 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001634432 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001634432 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0001634432 sbbp:WarrantsIssuedLoanAgreementTwoMember us-gaap:SubsequentEventMember 2017-07-14 2017-07-14 0001634432 sbbp:VestingSubjectToAccelerationMember sbbp:GranteeTwoMember 2017-01-01 2017-06-30 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember sbbp:GranteeFourMember 2017-01-01 2017-06-30 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember sbbp:GranteeFiveMember 2017-01-01 2017-06-30 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-06-30 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2016-02-26 2016-02-26 0001634432 sbbp:VestingBasedOnMarketAppreciationEventMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-06-30 0001634432 sbbp:ProductRevenueAllowanceAndReserveTradeDiscountMember 2017-01-01 2017-06-30 0001634432 sbbp:ProductRevenueAllowanceAndReserveMember 2017-01-01 2017-06-30 0001634432 sbbp:ProductRevenueAllowanceAndReserveGovernmentRebatesMember 2017-01-01 2017-06-30 0001634432 sbbp:ProductRevenueAllowanceAndReserveCoPayAssistanceProgramMember 2017-01-01 2017-06-30 0001634432 2017-04-01 2017-06-30 0001634432 2016-04-01 2016-06-30 0001634432 2016-01-01 2016-06-30 0001634432 sbbp:CreditFacility2017Member us-gaap:SubsequentEventMember 2017-07-14 0001634432 sbbp:CreditFacility2016TrancheTwoMember 2016-12-28 0001634432 sbbp:CreditFacility2016TrancheOneMember 2016-12-28 0001634432 2016-01-01 2016-12-31 0001634432 sbbp:CreditFacility2017Member us-gaap:SubsequentEventMember 2017-07-14 2017-07-14 0001634432 sbbp:CreditFacility2016Member 2017-03-31 0001634432 sbbp:CreditFacility2016Member 2016-12-28 2016-12-28 0001634432 sbbp:CreditFacility2016TrancheTwoMember 2016-12-28 2016-12-28 0001634432 sbbp:CreditFacility2016Member 2016-12-28 0001634432 sbbp:TaroPharmaceuticalIndustriesMember sbbp:AcquiredDevelopedProductRightsMember sbbp:KeveyisMember sbbp:SupplyAgreementMember 2016-12-01 2016-12-31 0001634432 sbbp:TaroPharmaceuticalIndustriesMember sbbp:AcquiredDevelopedProductRightsMember sbbp:KeveyisMember sbbp:AssetPurchaseAgreementMember 2016-12-31 0001634432 sbbp:WarrantsIssuedLoanAgreementOneMember sbbp:CreditFacility2016Member 2016-12-28 2016-12-28 0001634432 sbbp:AcquiredDevelopedProductRightsMember 2016-12-31 0001634432 2017-06-30 0001634432 2016-12-31 0001634432 2017-01-01 2017-06-30 utr:sqft sbbp:pharmacy sbbp:payment sbbp:product xbrli:shares iso4217:USD xbrli:shares xbrli:pure sbbp:item iso4217:USD false --12-31 Q2 2017 2017-06-30 6-K 0001634432 Non-accelerated Filer Strongbridge Biopharma plc 7500000 4207000 2574000 25078000 25921000 2400000 P10Y 7500000 P6Y 2 0.08 P6M P18M P30M P24M 150000 1.098 1.098 40000 40000 40000 40000 40000 40000 44000 44000 P6Y 40177000 P3Y 10000000 10000000 10000000 -24996000 -12841000 -59675000 -30191000 2 2 2 1 0.50 42000 159000 273000 72000 <div> <div> 3. Revenue recognition Product Revenue, Net   We sell Keveyis to one specialty pharmacy provider, (the “Customer”), who is the exclusive distributor of the Product in the United States.  The Customer subsequently resells the Product to patients, which are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of the Product.  Revenues from sales of Keveyis are recognized when we satisfy a performance obligation by transferring control of Keveyis to the Customer. Transfer of control occurs upon receipt of Keveyis by the Customer.  We expense incremental costs related to the set-up of the contract with the Customer when incurred as these costs did not meet the criteria for capitalization. Reserves for Variable Consideration   Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, co-pay assistance and other allowances that are offered between us and the patients’ payors.  There is no variable consideration reserve for returns as we do not accept returns of the Product.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than the Customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We will reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known. Trade Discount: We provide our Customer with a discount that is explicitly stated in our contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from our Customer. To the extent, the services received are distinct from our sale of products to the Customer, these payments are classified in selling, general and administrative expenses in our consolidated statement of operations and comprehensive loss. Funded Co-pay Assistance Program: We contract with a third-party to manage the co-pay assistance program intended to provide financial assistance to qualified insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with Product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. These payments are consideration payable to the customer and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. Government Rebates: We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated patient mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. Effective January 1, 2011, manufacturers of pharmaceutical products are responsible for 50% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this Medicare coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for the Product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. Temporary Supply and Patient Assistance Programs: We provide free Product to uninsured patients who satisfy pre-established criteria for either the Temporary Supply Program or the Patient Assistance Program.  Patients who meet the Temporary Supply Program eligibility criteria may receive a temporary supply of free Product for no more than sixty days while we are determining the patient’s third-party insurance, prescription drug benefit or other third-party coverage for the Product.  The Patient Assistance Program provides free Product for up to twelve months to patients that satisfy pre-established criteria for financial need.  We do not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in our consolidated statements of operations and comprehensive loss. To date, our only source of product revenue has been from the U.S. sales of the Product, which we began shipping to the Customer in April 2017.  The following table summarizes activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2017 (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Co-pay </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Trade </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> assistance </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Government </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> discount </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> program </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> rebates </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2016 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Provision related to current period sales </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 72 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 42 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 159 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 273 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Adjustment related to prior period sales </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Credit or payments made during the period </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (72) </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (35) </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (107) </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at June 30, 2017 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 159 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 166 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> <div> <div> The following table summarizes activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2017 (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Co-pay </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Trade </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> assistance </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Government </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> discount </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> program </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> rebates </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2016 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Provision related to current period sales </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 72 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 42 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 159 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 273 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Adjustment related to prior period sales </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Credit or payments made during the period </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (72) </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (35) </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (107) </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at June 30, 2017 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 159 </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 166 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> P1Y 1 P20D P20D 33.66 30.14 31.46 P12M P60D P7Y

1089000

1200000

616000

14868000

6958000

1110000

2573000

195975000

198508000

2533000

2418000

2222000

196000

112000

1090000

1177000

-87000

78000

2533000

2035000

498000

185000

1363000

1082000

281000

98000

282000

2511000

1255000

3293341

170000

6139647

222000

7428571

14743

5228000

137531000

103712000

67601000

37746000

33579000

51623000

33884000

66837000

33864000

33579000

-17739000

-32973000

250000

100000

2.45

7.37

428571

394289

<div> <div> 8. Commitments and contingencies (a)  Lease obligations In March 2015, we entered into a 52‑month building sublease agreement for 14,743 square feet of office space in Trevose, Pennsylvania. The lease has annual rent escalations and is recognized on a straight‑line basis over the term of the lease.  As of June 30, 2017, future minimum commitments under facility operating leases were as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Operating </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> leases </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 159 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 319 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 184 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 662 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Rent expense recognized under our operating lease, including additional rent charges for utilities, parking, maintenance and real estate taxes, was approximately $152,000 and $138,000 for the six months ended June 30, 2017 and 2016, respectively. (b) Commitments to Taro Pharmaceuticals Industries Ltd. In December 2016, we acquired the United States marketing rights to Keveyis® (dichlorphenamide) from a subsidiary of Taro.  Keveyis is approved in the United States to treat hyperkalemic, hypokalemic and related variants of primary periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.  Keveyis has received orphan drug exclusivity status in the United States through August 7, 2022.  Under the terms of an asset purchase agreement, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017, and will pay an aggregate of $7.5 million in potential milestones upon the achievement of certain product sales targets. Taro has agreed to continue to manufacture Keveyis for us under an exclusive supply agreement through the orphan exclusivity period. We are obligated to purchase certain annual minimum amounts of product totaling approximately $29 million over a six-year period. The supply agreement may extend beyond the orphan exclusivity period unless terminated by either party pursuant to the terms of the agreement. If terminated by Taro at the conclusion of the orphan exclusivity period, we have the right to manufacture the product on our own or have the product manufactured by a third party on our behalf. <div /></div> </div>

0.01

600000000

35335026

353000

<div> <div> As of June 30, 2017, future minimum commitments under facility operating leases were as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Operating </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> leases </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 159 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 319 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 184 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 662 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

377000

24737000

13814000

28081000

15902000

<div> <div> 7. Long-Term debt On December 28, 2016, we entered into a loan and security agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Horizon Technology Finance Corporation (“Horizon”) (collectively, the “Lenders”). The Loan Agreement provided for a $40 million credit facility, of which $20 million was borrowed initially. Under the Loan Agreement, we have access to two additional tranches of $10 million each, which would be available to us, subject to the achievement of certain specified milestones. The borrowings pursuant to the Loan Agreement mature after 48 months. The Loan Agreement provides for interest-only payments initially for the first 18 months of the loan followed by an amortization period of 30 months, a final payment fee equal to 8% of the amount borrowed, and interest payable at an annual rate equal to the sum of 8.22% plus the greater of 0.53% or the 30-day US LIBOR rate. The credit facility provides that if we satisfy certain milestones and borrows the final $10 million tranche, the interest-only period would be extended by an additional six months and the amortization period would be 24 months. We have granted a security interest in substantially all of its existing assets and assets acquired by us in the future, including intellectual property. The Loan Agreement contains facility and prepayment fees, and customary affirmative and negative covenants, including a financial covenant regarding minimum amounts of net revenue and events of default and restricts the payment of cash dividends.  The Loan Agreement contains a material adverse change clause whereby a material adverse change in our business, operations or financial condition would be considered an event of default whereby the lenders could declare all amounts under the Loan Agreement as immediately due and payable. We incurred $1.3 million in debt discounts and $0.3 million of debt issuance costs relating to this Loan Agreement, each of which have been recorded as a reduction to the long-term debt. These amounts will be amortized over the outstanding period of the debt to interest expense using the effective interest rate method. In connection with the execution of the Loan Agreement, we issued warrants to the Lenders to purchase an aggregate of 428,571 ordinary shares at an exercise price equal to $2.45 per share. The warrants were immediately exercisable and expire after ten years. We accounted for these warrants as equity, and the fair value was recorded into additional paid-in capital. On March 31, 2017, we entered into an amendment to the Loan Agreement that was made effective as of January 27, 2017 and provided for an extension to the dates by which our Swedish subsidiary was required to enter into security documents granting security interests on certain of its assets in favor of Oxford, as collateral agent for the Lender, and to increase the amount of debt we can incur under, and the amount of cash collateral it can provide for purposes of, our corporate credit card program from $100,000 to $250,000.  In connection with the amendment, we paid $150,000 to the Lenders. The $150,000 was recorded as additional debt discount cost and will be amortized as an adjustment of interest expense over the remaining term of the Loan. Future principal payments due under the Loan Agreement are as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Principal </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Payments </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,000 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,000 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8,000 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total future payments </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,000 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   On June 22, 2017, we notified the Lenders of our intentions to prepay our current Loan Agreement. Effective July 14, 2017 we retired the Loan Agreement and incurred a prepayment fee of $0.8 million and final payment interest charge of $1.6 million. <div /></div> </div>

0.0053

0.0822

P48M

P6Y

1300000

300000

-926000

1599000

5000

<div> <div> 10. Stock‑based compensation Our board of directors has adopted, the 2017 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of equity-based awards to new employees. The purpose of the Inducement Plan is to attract valued employees by offering them a greater stake in our success and a closer identity with us, and to encourage ownership of our ordinary shares by such employees. The Inducement Plan is effective as of February 23, 2017. As of June 30, 2017, 89,850 shares are available for issuance pursuant to the Inducement Plan. Our board of directors has adopted, and our shareholders have approved, the 2015 Equity Compensation Plan (the “2015 Plan”). The 2015 Plan provides for the grant of incentive stock options to our employees and any parent or subsidiary corporations’ employees, and for the grant of nonstatutory stock options, stock awards, and restricted stock units to our employees, directors and consultants and our parent or subsidiary corporations’ employees and consultants. The 2015 Plan is effective as of September 3, 2015.  As of June 30, 2017, 428,814 shares are available for issuance pursuant to the 2015 Plan. Our board of directors has adopted, and our shareholders have approved, the Non‑Employee Director Equity Compensation Plan (the “Non‑Employee Director Plan”). The Non‑Employee Director Plan provides for the grant of nonstatutory stock options, stock awards, and restricted stock units to our non‑employee directors. The Non‑Employee Director Plan is effective as of September 3, 2015.  As of June 30, 2017, 792 shares are available for issuance pursuant to the Non‑Employee Director Plan. A summary of our outstanding stock options as of June 30, 2017 is as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:41.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options Outstanding </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—January 1, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,249,784 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11.00 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.89 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,943,200 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.44 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited and cancelled </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (53,337) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.28 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—June 30, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,139,647 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.40 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.02 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,417 </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and exercisable—June 30, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,758,858 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.63 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.68 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,924 </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> Included in the stock options outstanding at June 30, 2017 are unvested stock options to purchase 88,908 shares at a weighted average exercise price of $18.80 per share for which the vesting of certain tranches will accelerate if the fair value per share of our stock reaches $31.46. In addition, the options outstanding include 97,652 shares that vest upon a market appreciation event, so long as it occurs prior to May 26, 2019 and 97,652 shares that will vest upon the one year anniversary of the market appreciation event. The market appreciation event, which had not yet occurred as of June 30, 2017, is defined as the last trading day in the period in which our closing stock price on each of 20 consecutive trading days reported on NASDAQ has been at least $30.14 or $33.66 for the respective grantee. Stock‑based compensation expense We recognized stock‑based compensation expense for employees and directors for stock options and RSUs in the accompanying unaudited consolidated statements of operations as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:19.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 281 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (87) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 498 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 196 </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,082 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,177 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,035 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,222 </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,363 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,090 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,533 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,418 </td> </tr> </table></div> As of June 30, 2017, the total unrecognized compensation expense related to unvested stock options, net of estimated forfeitures, is $11.3 million, which we expect to recognize over an estimated weighted‑average period of 2.92 years. In determining the estimated fair value of our service-based awards, we use the Black‑Scholes option‑pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment. The fair value of our service-based awards that were granted during the years was estimated with the following assumptions: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.20%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:36.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:36.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.95 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.87 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.78% - 2.26% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.3% - 1.6% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78.2% - 81.8% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78.1% - 83.6% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dividend rate </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Restricted Stock Units On February 26, 2016, our board of directors approved grants of restricted stock units (“RSUs”) to employees.  These RSUs vest two years from the date of issuance, provided that the employee is employed by us on such vesting date. All RSUs will fully vest upon a change of control of our company.  If and when the RSUs vest, we will issue one ordinary share for each whole RSU that has vested, subject to satisfaction of the executive’s tax withholding obligations. The RSUs will cease to be outstanding upon such issuance of ordinary shares.  We recorded expense, which is included in the stock-based compensation table above, of $98,000 and $78,000 for the three months ended June 30, 2017 and 2016, respectively, and $185,000 and $112,000 for the six months ended June 30, 2017 and 2016, respectively. As of June 30, 2017, the total unrecognized compensation expense related to unvested RSUs is $0.4 million, which we expect to recognize over an estimated weighted‑average period of 1.2 years. A summary of our unvested RSUs as of June 30, 2017 is as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested—January 1, 2017 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 184,000 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,000 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (2,000) </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested—June 30, 2017 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 222,000 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

-1.18

-0.61

-1.69

-0.86

1554000

1351000

P2Y11M1D

P1Y2M12D

400000

11300000

30147000

15219000

<div> <div> The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:65.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of June 30, 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33,579 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33,579 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 33,579 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 33,579 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrant liabilities </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,237 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,237 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 41,237 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 41,237 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:64.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of December 31, 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrant liabilities </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 4. Fair value measurement We follow FASB accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. Because of their short term nature, the amounts reported in the balance sheet for cash and cash equivalents, and accounts payable approximate fair value. The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows:  Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Because of their short term nature, the amounts reported in the balance sheet for cash and cash equivalents, and accounts payable approximate fair value. Level 2: Significant observable inputs other than Level 1 prices such as quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The fair values of the outstanding warrants were measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:65.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of June 30, 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33,579 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33,579 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 33,579 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 33,579 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrant liabilities </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,237 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,237 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 41,237 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 41,237 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:64.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of December 31, 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrant liabilities </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,090 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

40177000

29300000

37666000

P8Y

-44000

3000

-25000

-14000

7256000

15828000

<div> <div> 5. Intangible assets and goodwill The gross carrying amount of in‑process research and development, acquired developed product rights and goodwill is as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:65.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of June 30, 2017 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning of Period </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortization </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> IPR&D </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,723 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,723 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Acquired product rights </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,511) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 37,666 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 68,156 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,511) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 65,645 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:65.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of December 31, 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning of Period </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Impairment </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> IPR&D </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36,551 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (15,828) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,723 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Acquired product rights </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 43,807 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (15,828) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 68,156 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Our finite lived intangible asset consists of acquired developed product rights obtained from the asset acquisition of Keveyis® (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (“Taro”).  Keveyis is approved in the United States to treat hyperkalemic, hypokalemic and related variants of primary periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.  Keveyis has received orphan drug exclusivity status in the United States through August 7, 2022. In connection with the Asset Purchase Agreement and Supply Agreement we entered into with Taro, we have paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017.  We concluded that the supply price payable by us exceeds fair value and, therefore, used a discounted cash flow method with a probability assumption to value the payments in excess of fair value at $29.3 million, for which we have recorded an intangible asset and corresponding liability. This liability will be reduced as we purchase inventory over the term of the Supply Agreement.  In addition, we incurred transaction costs of $2.4 million, which were recorded in our Statement of Operations during the year ended December 31, 2016. The overall recording of the transaction resulted in the recording of an intangible asset of $40.2 million. This asset is being amortized over an eight-year period using the straight-line method.  We recorded amortization expense of $2.5 million and $0 for the six months ended June 30, 2017 and 2016, respectively.  <div /></div> </div>

15828000

-26027000

-13767000

-58173000

-30283000

255000

-926000

-871000

1502000

-92000

-827000

111000

616000

184000

433000

1403000

-825000

151000

95000

1099000

36551000

20723000

60900000

58389000

43807000

68156000

65645000

1474000

737000

1600000

762000

430000

1403000

<div> <div> Inventory Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Our inventory consists of only finished goods.  <div /></div> </div>

P52M

70559000

93882000

137531000

103712000

15957000

8158000

11090000

41237000

40000000

50000000

20000000

8000000

4000000

18434000

18566000

<div> <div> 1. Organizatio<a name="a1Organization_719123"></a>n Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Our first commercial product is Keveyis® (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration ("FDA") for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Keveyis has orphan drug exclusivity status in the United States through August 7, 2022. In addition to this neuromuscular disease product, we have two clinical-stage product candidates for rare endocrine diseases, Recorlev™ and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both Recorlev and veldoreotide have received orphan designation from the FDA and the European Medicines Agency ("EMA"). Given the well-identified and concentrated prescriber base addressing our target markets, we intend to use a small, focused sales force to effectively market Keveyis and our other products and product candidates, if approved, in the United States, the European Union and other key global markets. We believe that our ability to execute on this strategy is enhanced by the significant commercial and clinical development experience of key members of our management team. We will continue to identify and evaluate the potential acquisition of other products and product candidates that would be complementary to our existing rare neuromuscular and endocrine franchises or that would form the basis for new rare disease franchises. We believe this approach will enable us to maximize our commercial potential by further leveraging our existing resources and expertise. Liquidity As of June 30, 2017, we held cash and cash equivalents of $33.9 million. On July 14, 2017, we entered into a $50 million senior credit facility to retire our prior credit facility and provide us with additional capital. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. We intend to use the equity proceeds and the remainder of the initial loan proceeds (after deducting loan origination costs and other fees and expenses incurred in connection with the incurrence of the loan), plus any additional amounts that may be borrowed in the future, for general corporate purposes and working capital.  We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We believe the combination of our existing cash resources as of June 30, 2017 and the net proceeds from our July 14, 2017 debt and equity financing provides us with sufficient resources under our current operating plan, which includes the potential regulatory approval and launch of Recorlev, to achieve consistent positive cash flows from operating activities. We expect our funding requirements for operating activities to increase in 2017 and possibly beyond due to expenses associated with the commercialization of Keveyis, the execution of the Recorlev SONICS and LOGICS Phase 3 clinical trials, and our selling, general and administrative expenses. Our funding requirements will also increase to the extent we pursue potential in-licenses, acquisitions or similar transactions as part of our strategy. These expenses may be offset only in part by sales of Keveyis. To the extent our sales of Keveyis are less than we anticipate, or our expenses are higher than we anticipate, we may be required to fund our operations and capital needs through equity or debt financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us. Our loan and security agreement contains financial and non-financial covenants including minimum amounts of net revenue in 2017 and beyond. Failure to comply with the covenants could result in the lenders declaring the loan immediately due and payable. Our liquidity requirements are predicated on maintaining compliance with the debt covenants and repaying outstanding borrowings in accordance with the loan agreement. <div /></div> </div>

-150000

-7500000

-17739000

-25323000

-24996000

-12841000

-59675000

-30191000

-105000

-55000

<div> <div> Recent accounting pronouncements In January 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-04, Intangibles - Goodwill and Other:  Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This standard, which will be effective for the us beginning in the first quarter of fiscal year 2021, is required to be applied prospectively. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact this standard will have on its financial statements.   In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows in order to reduce diversity in practice. The guidance is effective for us beginning in the first quarter of fiscal year 2018. Early adoption is permitted. We are currently evaluating the impact of adopting this guidance on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Improvements to Employee Share-Based Payment Accounting,  which affects all entities that issue share-based payment awards to their employees. The amendments in this ASU cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess tax benefits on the statement of cash flows, an accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification and the classification of those taxes paid on the statement of cash flows. This ASU is effective for annual and interim periods beginning after December 15, 2016. This guidance can be applied either prospectively, retrospectively or using a modified retrospective transition method. Early adoption is permitted. We have adopted the standard effective January 1, 2017 and have elected to account for forfeitures as they occur as opposed to estimating forfeitures. The adoption of this standard did not have a material impact on our financial statements.  In February 2016, the FASB issued ASU No. 2016-02, Leases, that discusses how an entity should account for lease assets and lease liabilities. The guidance specifies that an entity who is a lessee under lease agreements should recognize lease assets and lease liabilities for those leases classified as operating leases under previous FASB guidance. Accounting for leases by lessors is largely unchanged under the new guidance. The guidance is effective for the us beginning in the first quarter of fiscal year 2019. Early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities,  that modifies certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The accounting standard update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption is permitted.  We are currently assessing the impact that adopting this new accounting guidance will have on our consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU No. 2015-11 applies only to inventory for which cost is determined by methods other than last in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. We adopted this standard on April 1, 2017. The adoption of this standard had no impact on the Company’s consolidated financial statements, there was no accounting impact to previously issued financial statements based on our adoption. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. We adopted this new standard on April 1, 2017 in conjunction with the launch of Keveyis. As we did not record revenue prior to the quarter ending June 30, 2017, there was no accounting impact to previously issued financial statements based on our adoption of ASC Topic 606.  <div /></div> </div>

-1290000

47000

-31621000

-15910000

-24737000

-13814000

-26552000

-14373000

662000

184000

319000

159000

138000

152000

<div> <div> 2. Summary of significant accounting policies and basis of presentation Basis of presentation These unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (U.S. GAAP). The unaudited consolidated financial statements reflect all adjustments, which include only normal recurring adjustments that are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented. The preparation of the unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the consolidated financial statements.  Actual results could differ from those estimates. These unaudited consolidated financial statements should be read in conjunction with the accounting policies and notes to the audited consolidated financial statements included in Strongbridge Biopharma’s 2016 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2017.  Operating results for the six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. Revenue recognition Prior to the April 2017 launch of Keveyis, we have not previously generated any revenue. Therefore, we adopted Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, effective April 1, 2017.  Topic 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.  Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We apply the five-step model to contracts only when it is probable that we will collect the consideration we are entitled to receive in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for net product revenue, see Note 3, "Revenue Recognition". Inventory Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Our inventory consists of only finished goods.  Foreign currency translation The consolidated financial statements are reported in United States dollars, which is our functional currency, including each of our consolidated subsidiaries. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange gain (loss) in our consolidated statements of operations. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. We must apply significant judgment in this process. Actual results could materially differ from those estimates. Net loss per share Basic net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of shares of ordinary shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted‑average number of shares of ordinary shares outstanding for the period, including any dilutive effect from outstanding stock options or other equity-based awards. Shares used in the diluted net loss per share calculations exclude anti‑dilutive ordinary shares equivalents, which currently consist of outstanding stock options, unvested restricted stock units and warrants. The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of June 30, 2017 and 2016, as they would be anti-dilutive: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,428,571 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options issued and outstanding </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,139,647 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,293,341 </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested restricted stock units </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 222,000 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 170,000 </td> </tr> </table></div>   Recent accounting pronouncements In January 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-04, Intangibles - Goodwill and Other:  Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This standard, which will be effective for the us beginning in the first quarter of fiscal year 2021, is required to be applied prospectively. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact this standard will have on its financial statements.   In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows in order to reduce diversity in practice. The guidance is effective for us beginning in the first quarter of fiscal year 2018. Early adoption is permitted. We are currently evaluating the impact of adopting this guidance on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Improvements to Employee Share-Based Payment Accounting,  which affects all entities that issue share-based payment awards to their employees. The amendments in this ASU cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess tax benefits on the statement of cash flows, an accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification and the classification of those taxes paid on the statement of cash flows. This ASU is effective for annual and interim periods beginning after December 15, 2016. This guidance can be applied either prospectively, retrospectively or using a modified retrospective transition method. Early adoption is permitted. We have adopted the standard effective January 1, 2017 and have elected to account for forfeitures as they occur as opposed to estimating forfeitures. The adoption of this standard did not have a material impact on our financial statements.  In February 2016, the FASB issued ASU No. 2016-02, Leases, that discusses how an entity should account for lease assets and lease liabilities. The guidance specifies that an entity who is a lessee under lease agreements should recognize lease assets and lease liabilities for those leases classified as operating leases under previous FASB guidance. Accounting for leases by lessors is largely unchanged under the new guidance. The guidance is effective for the us beginning in the first quarter of fiscal year 2019. Early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities,  that modifies certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The accounting standard update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption is permitted.  We are currently assessing the impact that adopting this new accounting guidance will have on our consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU No. 2015-11 applies only to inventory for which cost is determined by methods other than last in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. We adopted this standard on April 1, 2017. The adoption of this standard had no impact on the Company’s consolidated financial statements, there was no accounting impact to previously issued financial statements based on our adoption. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. We adopted this new standard on April 1, 2017 in conjunction with the launch of Keveyis. As we did not record revenue prior to the quarter ending June 30, 2017, there was no accounting impact to previously issued financial statements based on our adoption of ASC Topic 606.    <div /></div> </div>

497000

30000

150000

301000

-1246000

44000

25000

60000

550000

800000

150000

7500000

1000000

7500000

764000

1863000

40000000

20000000

-25101000

-12896000

-59675000

-30191000

25000

20000

29000000

11366000

4572000

7609000

4128000

-129400000

-189075000

1529000

<div> <div> Accrued liabilities consist of the following (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Consulting and professional fees </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,573 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,110 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued payable due Taro Pharmaceuticals Industries Ltd. </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued interest </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 430 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Supply agreement - current portion </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,574 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,207 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Employee compensation </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,351 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,554 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 30 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 497 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total accrued liabilities </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,958 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,868 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,428,571 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options issued and outstanding </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,139,647 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,293,341 </td> </tr> <tr> <td valign="bottom" style="width:71.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested restricted stock units </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 222,000 </td> <td valign="middle" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:00.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 170,000 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> We recognized stock‑based compensation expense for employees and directors for stock options and RSUs in the accompanying unaudited consolidated statements of operations as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:19.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 281 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (87) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 498 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 196 </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,082 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,177 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,035 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,222 </td> </tr> <tr> <td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,363 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,090 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,533 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,418 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The gross carrying amount of in‑process research and development, acquired developed product rights and goodwill is as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:65.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of June 30, 2017 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning of Period </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortization </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> IPR&D </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,723 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,723 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Acquired product rights </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,511) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 37,666 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 68,156 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,511) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 65,645 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:65.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of December 31, 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning of Period </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additions </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Impairment </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> IPR&D </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36,551 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (15,828) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,723 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Acquired product rights </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 43,807 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,177 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (15,828) </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 68,156 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Future principal payments due under the Loan Agreement are as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Principal </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Payments </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,000 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,000 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8,000 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total future payments </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,000 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested—January 1, 2017 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 184,000 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 40,000 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (2,000) </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested—June 30, 2017 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 222,000 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:41.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options Outstanding </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—January 1, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,249,784 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11.00 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.89 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,943,200 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.44 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited and cancelled </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (53,337) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.28 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—June 30, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,139,647 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.40 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.02 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,417 </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and exercisable—June 30, 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,758,858 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.63 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.68 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,924 </td> <td valign="bottom" style="width:00.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.20%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:36.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:36.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.95 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.87 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.78% - 2.26% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.3% - 1.6% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78.2% - 81.8% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78.1% - 83.6% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dividend rate </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

8143000

4014000

17584000

10142000

2418000

2533000

P2Y

2000

40000

184000

222000

P5Y10M13D

P5Y11M12D

0.836

0.818

0.781

0.782

0.016

0.0226

0.013

0.0178

428814

89850

792

1924000

1758858

10.63

P5Y8M5D

53337

2943200

14417000

3249784

6139647

88908

97652

11.00

7.40

18.80

P6Y10M21D

P8Y7D

8.28

3.44

6.98

40000

35335026

40000

35335026

66972000

44000

195975000

353000

-129400000

9830000

44000

198508000

353000

-189075000

3000000

<div> <div>                                 11. Subsequent Events On July 14, 2017, we entered into a $50 million senior credit facility with CRG LP (“CRG”), a healthcare-focused investment firm, to retire our existing debt facility and provide additional capital to us. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with this first tranche, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. The term loan agreement has a six-year term with three years of interest-only payments. The interest-only period may be extended to six years based upon the achievement of certain milestones during the first three years of the loan term. As a condition to the new credit facility, we issued warrants with a seven-year term to CRG to purchase 394,289 ordinary shares at an exercise price of $7.37 per share. In addition, pursuant to terms of the new credit facility, we used a portion of the initial loan proceeds to repay all of the amounts we owed under the Loan Agreement to Oxford and Horizon, and the other lenders named therein. We intend to use the remainder of the initial loan proceeds (after deducting loan origination costs and other fees and expenses incurred in connection with the incurrence of the loan), plus any additional amounts that may be borrowed in the future, for general corporate purposes and working capital.                   <div /></div> </div>

7000

159000

166000

35000

107000

72000

11090000

41237000

21205382

35335026

EX-101.SCH 3 sbbp-20170630.xsd EX-101.SCH 00100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Cash Flow link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Fair value measurement (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Intangible assets and goodwill - Components (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Long Term Debt - Future principal payments (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Commitments and contingencies - Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statement of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of significant accounting policies and basis of presentation link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Revenue recognition link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Fair value measurement link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued liabilities link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Long Term Debt link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Revenue recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Fair value measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accrued liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Long Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization - Products (Details) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - Organization - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of significant accounting policies and basis of presentation - Antidilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Revenue recognition - General (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Revenue recognition - Allowance and Reserve (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Intangible assets and goodwill - Asset purchase (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Long Term Debt - Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Long Term Debt - Prepayment (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Commitments and contingencies - Commitments to Taro (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Stock-based compensation - General (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Stock-based compensation - Stock options (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Stock-based compensation - Options outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - Stock-based compensation - Stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 41005 - Disclosure - Stock-based compensation - Fair value assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 41006 - Disclosure - Stock-based compensation - Restricted stock units (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Subsequent events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 sbbp-20170630_cal.xml EX-101.CAL EX-101.DEF 5 sbbp-20170630_def.xml EX-101.DEF EX-101.LAB 6 sbbp-20170630_lab.xml EX-101.LAB No definition available. Document and Entity Information [Abstract] Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Document Fiscal Year Focus Document Fiscal Period Focus Consolidated Balance Sheets Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents—end of period Cash and cash equivalents—beginning of period Cash and cash equivalents Cash Accounts Receivable, Net, Current Accounts receivable Inventory, Net Inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Deferred Tax Assets, Net, Noncurrent Deferred tax asset Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Goodwill Goodwill, End of Period Goodwill, Beginning of Period Goodwill Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Accrued Liabilities, Current [Abstract] Current liabilities: Accounts Payable Accounts payable Accrued Liabilities, Current Accrued liabilities Total accrued liabilities Liabilities, Current Total current liabilities Long-term Debt, Excluding Current Maturities Long-term debt Warrants and Rights Outstanding Warrant liabilities Warrant liability Carrying value as of the balance sheet date of obligations incurred through that date and due beyond one year (or beyond one operating cycle if longer) in connection with supply agreement. Accrued Liabilities, Supply Agreement, Noncurrent Supply agreement liability, noncurrent Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 8) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders’ equity: Aggregate par or state value of deferred shares issued in order to satisfy legislative requirement to maintain a minimum level of issued share capital denominated in euro. Deferred Shares, Value Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at June 30, 2017 and December 31, 2016 Common Stock, Value, Issued Ordinary shares, $0.01 par value, 600,000,000 shares authorized at June 30, 2017 and December 31, 2016; 35,335,026 shares issued and outstanding at June 30, 2017 and December 31, 2016 Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance at end of period Balance at beginning of period Total stockholders’ equity Liabilities and Equity Total liabilities and stockholders’ equity Face amount or stated value per share of deferred shares. Deferred Shares, Par Or Stated Value Per Share Deferred shares, par value (in dollars per share) The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws. Deferred Shares , Shares Authorized Deferred shares, shares authorized Total number of deferred shares of an entity that have been sold or granted to shareholders (includes related deferred shares that were issued, repurchased, and remain in the treasury). Deferred Shares , Shares Issued Deferred shares, shares issued Number of deferred stock of stock outstanding. Deferred Shares, Shares Outstanding Deferred shares, shares outstanding Common Stock, Par or Stated Value Per Share Ordinary shares, par value (in dollars per share) Common Stock, Shares Authorized Ordinary shares, shares authorized Common Stock, Shares, Issued Ordinary shares, shares issued Common Stock, Shares, Outstanding Ordinary shares, shares outstanding Consolidated Statements of Operations and Comprehensive Loss Revenues [Abstract] Revenues: Revenue, Net Net product sales Revenues Total revenues Operating Expenses [Abstract] Cost and expenses: Cost of Goods Sold Cost of sales (excluding amortization of intangible asset) Research and Development Expense Research and development Selling, General and Administrative Expense Selling, general and administrative Amortization of intangible asset Acquired product rights, Amortization Total, Amortization Amortization of intangible asset Asset Impairment Charges Impairment of intangible asset Operating Expenses Total cost and expenses Operating Income (Loss) Operating loss Nonoperating Income (Expense) [Abstract] Other income (expense), net: Fair Value Adjustment of Warrants Unrealized loss on fair value of warrants Change in fair value of warrant liability Interest Expense Interest expense Foreign Currency Transaction Gain (Loss), before Tax Foreign exchange (loss) gain Other Nonoperating Income (Expense) Other income (expense), net Nonoperating Income (Expense) Total other income (expense), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Income tax (expense) benefit Income tax expense Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net loss Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to non-controlling interest Net Income (Loss) Attributable to Parent Net loss attributable to Strongbridge Biopharma No definition available. Net Income (Loss) Available to Common Stockholders, Basic and Diluted [Abstract] Net loss attributable to ordinary shareholders: Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period). Also includes Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions. Net Income (Loss) Available to Common Stockholders, Basic and Diluted Basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Net loss per share attributable to ordinary shareholders: Earnings Per Share, Basic and Diluted Basic and diluted Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted-average shares used in computing net loss per share attributable to ordinary shareholders: Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted Consolidated Statements of Shareholders’ Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Consolidated Statements of Cash Flow Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation Amortization of Debt Issuance Costs and Discounts Amortization of debt discounts and debt issuance costs Deferred Income Tax Expense (Benefit) Deferred income tax expense (benefit) Depreciation Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net Impairment/loss on investment in Antisense Therapeutics Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Noncurrent Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued liabilities and other liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Businesses and Interest in Affiliates Payments for acquisition Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Payments of Debt Issuance Costs Payment for amendment of long-term debt Payment for amendment of long-term debt Proceeds from Issuance of Debt Proceeds from long-term debt Net Cash Provided by (Used in) Financing Activities Net cash used in financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information - Cash paid during the year for: Income Taxes Paid, Net Income taxes other, net of refunds Interest Paid, Net Interest Organization Nature of Operations [Text Block] Organization Summary of significant accounting policies and basis of presentation Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Summary of significant accounting policies and basis of presentation Revenue recognition Disclosure pertaining to revenue. Revenues Disclosure [Text Block] Revenue recognition Fair value measurement Fair Value Disclosures [Text Block] Fair value measurement Intangible assets and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Intangible assets and goodwill Accrued liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued liabilities Debt Disclosure Debt Disclosure [Text Block] Long Term Debt Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Income taxes Income Tax Disclosure [Text Block] Income taxes Stock-based compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock based compensation Subsequent events Subsequent Events [Text Block] Subsequent events Basis of Accounting, Policy [Policy Text Block] Basis of presentation Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Inventory, Policy [Policy Text Block] Inventory Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign currency translation Use of Estimates, Policy [Policy Text Block] Use of estimates Earnings Per Share, Policy [Policy Text Block] Net loss per share New Accounting Pronouncements, Policy [Policy Text Block] Recent accounting pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities excluded from computations of diluted weighted average shares outstanding Tabular disclosure pertaining to revenue of the entity. Schedule of Revenue [Table Text Block] Summary of product revenue allowance and reserve categories Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of fair value of financial assets by level Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of gross carrying amount of in process research and development and goodwill Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued liabilities Schedule of Maturities of Long-term Debt [Table Text Block] Future principal payments Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of future minimum commitments under facility operating leases Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of summary of outstanding stock options activity Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions for estimating fair value of stock option awards Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of summary of unvested RSUs Number of clinical-stage product candidates. Number of Clinical-Stage Product Candidates Number of clinical-stage product candidates Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Debt No definition available. Liquidity [Abstract] Liquidity Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity The additional borrowing capacity available under the credit facility, upon achievement of certain specified milestones. Line Of Credit Facility, Contingent Additional Borrowing Capacity Additional borrowing capacity on achievement of milestones Stock Issued During Period, Value, New Issues Issuance of shares Shares Issued, Price Per Share Price per share (in dollars per share) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Earnings Per Share [Abstract] Net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive shares of common stock (in shares) Represents the number of specialty pharmacy providers. Number of Specialty Pharmacy Provider Number of specialty pharmacy providers Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Line Items] Reserves for Variable Consideration Revenue Recognition, Sales Returns, Reserve for Sales Returns Reserve for returns Represents the percentage of patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. Percentage of Patient’s Cost of Branded Prescription Drugs Related to the Medicare Part D Coverage Gap Percentage of patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap for which manufacturers of pharmaceutical products are responsible Maximum period for which patients may receive free product under temporary supply program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Threshold Period for Patients Who Receive a Temporary Supply of Free Product Maximum period for which patients may receive free product under Temporary Supply Program Maximum period for which patients may receive free product under patient assistance program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Threshold Period for Patients Who Receive Free Product Under Patient Assistance Program Maximum period for which patients may receive free product under Patient Assistance Program Movement in Valuation Allowances and Reserves [Roll Forward] Product revenue allowance and reserves Valuation Allowances and Reserves, Balance Balance at end of period Balance at beginning of period Amount of increase in the allowances and reserves, related to current period sales. Revenue Allowances and Reserves, Provision Related To Current Period Sales Provision related to current period sales Valuation Allowances and Reserves, Deductions Credit or payments made during the period Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets, Fair Value Disclosure [Abstract] Assets Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Assets, Fair Value Disclosure Total Assets Liabilities, Fair Value Disclosure [Abstract] Liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Total liabilities Schedule of intangible assets and goodwill. Schedule of Intangible Assets and Goodwill [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Intangible Assets and Goodwill [Line Items] In-process research and development and Goodwill Indefinite-Lived Intangible Assets (Excluding Goodwill) IPR&D, End of Period IPR&D, Beginning of Period Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) IPR&D, Impairment Finite-Lived Intangible Assets, Gross Acquired product rights, End of Period Acquired product rights, Beginning of Period Acquired product rights Finite-lived Intangible Assets Acquired Acquired product rights, Additions Intangible Assets, Net (Including Goodwill) Total, End of Period Total, Beginning of Period Amount of increase in assets, excluding financial assets, lacking physical substance and amount of increase in goodwill resulting from a business combination. Intangible Assets and Goodwill Acquired Total, Additions Goodwill and Intangible Asset Impairment Total Impairment Represents the number of installment payments. Number of Installment Payments Number of installment payments Payments to Acquire Intangible Assets Installment payment Amount of direct costs of the asset acquisition including legal, accounting, and other costs incurred to consummate the transaction. Asset Acquisition, Transaction Costs Transaction costs EX-101.PRE 7 sbbp-20170630_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Strongbridge Biopharma plc
Entity Central Index Key	0001634432
Document Type	6-K
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2

XML 9 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 33,864	$ 66,837
Accounts receivable	616
Inventory	1,403
Prepaid expenses and other current assets	1,863	764
Total current assets	37,746	67,601
Property and equipment, net	20	25
Deferred tax asset		1,599
Intangible assets, net	58,389	60,900
Goodwill	7,256	7,256
Other assets	301	150
Total assets	103,712	137,531
Current liabilities:
Accounts payable	1,200	1,089
Accrued liabilities	6,958	14,868
Total current liabilities	8,158	15,957
Long-term debt	18,566	18,434
Warrant liability	41,237	11,090
Supply agreement liability, noncurrent	25,921	25,078
Total liabilities	93,882	70,559
Commitments and contingencies (Note 8)
Stockholders’ equity:
Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at June 30, 2017 and December 31, 2016	44	44
Ordinary shares, $0.01 par value, 600,000,000 shares authorized at June 30, 2017 and December 31, 2016; 35,335,026 shares issued and outstanding at June 30, 2017 and December 31, 2016	353	353
Additional paid-in capital	198,508	195,975
Accumulated deficit	(189,075)	(129,400)
Total stockholders’ equity	9,830	66,972
Total liabilities and stockholders’ equity	$ 103,712	$ 137,531

XML 10 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Consolidated Balance Sheets
Deferred shares, par value (in dollars per share)	$ 1.098	$ 1.098
Deferred shares, shares authorized	40,000	40,000
Deferred shares, shares issued	40,000	40,000
Deferred shares, shares outstanding	40,000	40,000
Ordinary shares, par value (in dollars per share)	$ 0.01	$ 0.01
Ordinary shares, shares authorized	600,000,000	600,000,000
Ordinary shares, shares issued	35,335,026	35,335,026
Ordinary shares, shares outstanding	35,335,026	35,335,026

XML 11 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Net product sales	$ 1,529		$ 1,529
Total revenues	1,529		1,529
Cost and expenses:
Cost of sales (excluding amortization of intangible asset)	377		377
Research and development	4,128	$ 4,572	7,609	$ 11,366
Selling, general and administrative	10,142	4,014	17,584	8,143
Amortization of intangible asset	1,255		2,511
Impairment of intangible asset		5,228		5,228
Total cost and expenses	15,902	13,814	28,081	24,737
Operating loss	(14,373)	(13,814)	(26,552)	(24,737)
Other income (expense), net:
Unrealized loss on fair value of warrants	(15,219)		(30,147)
Interest expense	(737)		(1,474)
Foreign exchange (loss) gain	(14)	3	(25)	(44)
Other income (expense), net	60	44	25	(1,246)
Total other income (expense), net	(15,910)	47	(31,621)	(1,290)
Loss before income taxes	(30,283)	(13,767)	(58,173)	(26,027)
Income tax (expense) benefit	92	871	(1,502)	926
Net loss	(30,191)	(12,896)	(59,675)	(25,101)
Net loss attributable to non-controlling interest		55		105
Net loss attributable to Strongbridge Biopharma	(30,191)	(12,841)	(59,675)	(24,996)
Net loss attributable to ordinary shareholders:
Basic and diluted	$ (30,191)	$ (12,841)	$ (59,675)	$ (24,996)
Net loss per share attributable to ordinary shareholders:
Basic and diluted	$ (0.86)	$ (0.61)	$ (1.69)	$ (1.18)
Weighted-average shares used in computing net loss per share attributable to ordinary shareholders:
Basic and diluted	35,335,026	21,205,382	35,335,026	21,205,382

XML 12 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Shareholders' Equity - 6 months ended Jun. 30, 2017 - USD ($) $ in Thousands	Ordinary Shares	Deferred Shares	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at beginning of period at Dec. 31, 2016	$ 353	$ 44	$ 195,975	$ (129,400)	$ 66,972
Balance (in shares) at Dec. 31, 2016	35,335,026	40,000
Increase (Decrease) in Stockholders' Equity
Net loss				(59,675)	(59,675)
Stock-based compensation			2,533		2,533
Balance at end of period at Jun. 30, 2017	$ 353	$ 44	$ 198,508	$ (189,075)	$ 9,830
Balance (in shares) at Jun. 30, 2017	35,335,026	40,000

XML 13 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flow - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (59,675)	$ (25,101)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability	30,147
Stock-based compensation	2,533	2,418
Amortization of intangible asset	2,511
Amortization of debt discounts and debt issuance costs	282
Deferred income tax expense (benefit)	1,599	(926)
Depreciation	5	5
Impairment of intangible asset		5,228
Impairment/loss on investment in Antisense Therapeutics		550
Changes in operating assets and liabilities:
Accounts receivable	(616)
Inventory	(1,403)
Prepaid expenses and other current assets	(1,099)	(95)
Other assets	(151)	825
Accounts payable	111	(827)
Accrued liabilities and other liabilities	433	184
Net cash used in operating activities	(25,323)	(17,739)
Cash flows from investing activities:
Payments for acquisition	(7,500)
Net cash used in investing activities	(7,500)
Cash flows from financing activities:
Payment for amendment of long-term debt	(150)
Net cash used in financing activities	(150)
Net decrease in cash and cash equivalents	(32,973)	(17,739)
Cash and cash equivalents—beginning of period	66,837	51,623
Cash and cash equivalents—end of period	33,864	$ 33,884
Supplemental disclosures of cash flow information - Cash paid during the year for:
Income taxes other, net of refunds	255
Interest	$ 762

XML 14 R7.htm IDEA: XBRL DOCUMENT

Organization	6 Months Ended
Organization	Jun. 30, 2017
Organization
Organization	1. Organization Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Our first commercial product is Keveyis® (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration ("FDA") for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Keveyis has orphan drug exclusivity status in the United States through August 7, 2022. In addition to this neuromuscular disease product, we have two clinical-stage product candidates for rare endocrine diseases, Recorlev™ and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both Recorlev and veldoreotide have received orphan designation from the FDA and the European Medicines Agency ("EMA"). Given the well-identified and concentrated prescriber base addressing our target markets, we intend to use a small, focused sales force to effectively market Keveyis and our other products and product candidates, if approved, in the United States, the European Union and other key global markets. We believe that our ability to execute on this strategy is enhanced by the significant commercial and clinical development experience of key members of our management team. We will continue to identify and evaluate the potential acquisition of other products and product candidates that would be complementary to our existing rare neuromuscular and endocrine franchises or that would form the basis for new rare disease franchises. We believe this approach will enable us to maximize our commercial potential by further leveraging our existing resources and expertise. Liquidity As of June 30, 2017, we held cash and cash equivalents of $33.9 million. On July 14, 2017, we entered into a $50 million senior credit facility to retire our prior credit facility and provide us with additional capital. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with the initial borrowing, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. We intend to use the equity proceeds and the remainder of the initial loan proceeds (after deducting loan origination costs and other fees and expenses incurred in connection with the incurrence of the loan), plus any additional amounts that may be borrowed in the future, for general corporate purposes and working capital. We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We believe the combination of our existing cash resources as of June 30, 2017 and the net proceeds from our July 14, 2017 debt and equity financing provides us with sufficient resources under our current operating plan, which includes the potential regulatory approval and launch of Recorlev, to achieve consistent positive cash flows from operating activities. We expect our funding requirements for operating activities to increase in 2017 and possibly beyond due to expenses associated with the commercialization of Keveyis, the execution of the Recorlev SONICS and LOGICS Phase 3 clinical trials, and our selling, general and administrative expenses. Our funding requirements will also increase to the extent we pursue potential in-licenses, acquisitions or similar transactions as part of our strategy. These expenses may be offset only in part by sales of Keveyis. To the extent our sales of Keveyis are less than we anticipate, or our expenses are higher than we anticipate, we may be required to fund our operations and capital needs through equity or debt financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us. Our loan and security agreement contains financial and non-financial covenants including minimum amounts of net revenue in 2017 and beyond. Failure to comply with the covenants could result in the lenders declaring the loan immediately due and payable. Our liquidity requirements are predicated on maintaining compliance with the debt covenants and repaying outstanding borrowings in accordance with the loan agreement.

XML 15 R8.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies and basis of presentation

6 Months Ended

Jun. 30, 2017

Summary of significant accounting policies and basis of presentation

Summary of significant accounting policies and basis of presentation

2. Summary of significant accounting policies and basis of presentation

Basis of presentation

Revenue recognition

Inventory

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Our inventory consists of only finished goods.

Foreign currency translation

Use of estimates

Net loss per share

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of June 30, 2017 and 2016, as they would be anti-dilutive:


	Six Months Ended
	June 30,
	2017		2016
Warrants		7,428,571		—
Stock options issued and outstanding		6,139,647		3,293,341
Unvested restricted stock units		222,000		170,000

Recent accounting pronouncements

XML 16 R9.htm IDEA: XBRL DOCUMENT

Revenue recognition

6 Months Ended

Jun. 30, 2017

Revenue recognition

Revenue recognition

3. Revenue recognition

Product Revenue, Net

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, co-pay assistance and other allowances that are offered between us and the patients’ payors. There is no variable consideration reserve for returns as we do not accept returns of the Product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than the Customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We will reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known.



				Co-pay
		Trade		assistance		Government
		discount		program		rebates		Total
Balance at December 31, 2016	$	—	$	—	$	—	$	—
Provision related to current period sales		72		42		159		273
Adjustment related to prior period sales		—		—		—		—
Credit or payments made during the period		(72)		(35)		—		(107)
Balance at June 30, 2017	$	—	$	7	$	159	$	166

XML 17 R10.htm IDEA: XBRL DOCUMENT

Fair value measurement

6 Months Ended

Jun. 30, 2017

Fair value measurement

Fair value measurement

4. Fair value measurement

The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows:

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):


	As of June 30, 2017
	Level I		Level II		Level III		Total
Cash equivalents		33,579		—		—		33,579
Total assets	$	33,579	$	—	$	—	$	33,579
Warrant liabilities		—		—		41,237		41,237
Total liabilities	$	—	$	—	$	41,237	$	41,237


	As of December 31, 2016
	Level I		Level II		Level III		Total
Warrant liabilities		—		—		11,090		11,090
Total liabilities	$	—	$	—	$	11,090	$	11,090

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 18 R11.htm IDEA: XBRL DOCUMENT

Intangible assets and goodwill

6 Months Ended

Jun. 30, 2017

Intangible assets and goodwill

Intangible assets and goodwill

5. Intangible assets and goodwill

The gross carrying amount of in‑process research and development, acquired developed product rights and goodwill is as follows (in thousands):


	As of June 30, 2017
	Beginning of Period		Additions		Amortization		End of Period
IPR&D	$	20,723	$	—	$	—	$	20,723
Acquired product rights		40,177		—		(2,511)		37,666
Goodwill		7,256		—		—		7,256
Total	$	68,156	$	—	$	(2,511)	$	65,645


	As of December 31, 2016
	Beginning of Period		Additions		Impairment		End of Period
IPR&D	$	36,551	$	—	$	(15,828)	$	20,723
Acquired product rights		—		40,177		—		40,177
Goodwill		7,256		—		—		7,256
Total	$	43,807	$	40,177	$	(15,828)	$	68,156

We recorded amortization expense of $2.5 million and $0 for the six months ended June 30, 2017 and 2016, respectively.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 19 R12.htm IDEA: XBRL DOCUMENT

Accrued liabilities

6 Months Ended

Jun. 30, 2017

Accrued liabilities

Accrued liabilities

6. Accrued liabilities

Accrued liabilities consist of the following (in thousands):


	June 30,		December 31,
	2017		2016
Consulting and professional fees	$	2,573	$	1,110
Accrued payable due Taro Pharmaceuticals Industries Ltd.		—		7,500
Accrued interest		430		—
Supply agreement - current portion		2,574		4,207
Employee compensation		1,351		1,554
Other		30		497
Total accrued liabilities	$	6,958	$	14,868

XML 20 R13.htm IDEA: XBRL DOCUMENT

Long Term Debt

6 Months Ended

Jun. 30, 2017

Debt Disclosure

Long Term Debt

7. Long-Term debt

Future principal payments due under the Loan Agreement are as follows (in thousands):


	Principal
	Payments

2017	$	—
2018		4,000
2019		8,000
2020		8,000
Total future payments	$	20,000

XML 21 R14.htm IDEA: XBRL DOCUMENT

Commitments and contingencies

6 Months Ended

Jun. 30, 2017

Commitments and contingencies

Commitments and contingencies

8. Commitments and contingencies

(a) Lease obligations

As of June 30, 2017, future minimum commitments under facility operating leases were as follows (in thousands):


	Operating
	leases

2017	$	159
2018		319
2019		184
Total minimum lease payments	$	662

(b) Commitments to Taro Pharmaceuticals Industries Ltd.

XML 22 R15.htm IDEA: XBRL DOCUMENT

Income taxes	6 Months Ended
Income taxes	Jun. 30, 2017
Income taxes
Income taxes	9. Income taxes Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized. We assess our ability to realize deferred tax assets. Changes in future earnings projections, among other factors, may cause us to adjust our valuation allowance on deferred tax assets. Any such adjustments would impact our income tax expense in the period in which it is determined that these factors have changed. For the six months ended June 30, 2017, we recorded a full valuation allowance against our deferred tax asset, resulting in income tax expense of $1.5 million.

XML 23 R16.htm IDEA: XBRL DOCUMENT

Stock-based compensation

6 Months Ended

Jun. 30, 2017

Stock-based compensation

Stock based compensation

10. Stock‑based compensation

A summary of our outstanding stock options as of June 30, 2017 is as follows:


	Options Outstanding
				Weighted-
				Average
		Weighted-		Remaining
		Average		Contractual
	Number of	Exercise		Term	Aggregate
	Shares	Price		(Years)	Intrinsic Value
					(in thousands)
Outstanding—January 1, 2017	3,249,784	$	11.00	6.89	$	—
Granted	2,943,200	$	3.44
Forfeited and cancelled	(53,337)	$	8.28
Exercised	—		—
Outstanding—June 30, 2017	6,139,647	$	7.40	8.02	$	14,417
Vested and exercisable—June 30, 2017	1,758,858	$	10.63	5.68	$	1,924

Stock‑based compensation expense

We recognized stock‑based compensation expense for employees and directors for stock options and RSUs in the accompanying unaudited consolidated statements of operations as follows (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016
Research and development	$	281	$	(87)	$	498	$	196
General and administrative		1,082		1,177		2,035		2,222
Total stock-based compensation	$	1,363	$	1,090	$	2,533	$	2,418

The fair value of our service-based awards that were granted during the years was estimated with the following assumptions:


	Six Months Ended
	June 30,
	2017	2016
Expected term (in years)	5.95	5.87
Risk-free interest rate	1.78% - 2.26%	1.3% - 1.6%
Expected volatility	78.2% - 81.8%	78.1% - 83.6%
Dividend rate	—%	—%

Restricted Stock Units

A summary of our unvested RSUs as of June 30, 2017 is as follows:


		Number of
		Shares
Unvested—January 1, 2017		184,000
Granted		40,000
Forfeited		(2,000)
Vested		—
Unvested—June 30, 2017		222,000

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 24 R17.htm IDEA: XBRL DOCUMENT

Subsequent events	6 Months Ended
Subsequent events	Jun. 30, 2017
Subsequent events
Subsequent events	11. Subsequent Events On July 14, 2017, we entered into a $50 million senior credit facility with CRG LP (“CRG”), a healthcare-focused investment firm, to retire our existing debt facility and provide additional capital to us. We initially borrowed $40 million under the term loan agreement and have the option to borrow an additional $10 million based upon the achievement of a certain revenue milestone on or prior to June 30, 2018. Concurrent with this first tranche, CRG purchased $3 million of our ordinary shares at a price of $6.98 per share. The term loan agreement has a six-year term with three years of interest-only payments. The interest-only period may be extended to six years based upon the achievement of certain milestones during the first three years of the loan term. As a condition to the new credit facility, we issued warrants with a seven-year term to CRG to purchase 394,289 ordinary shares at an exercise price of $7.37 per share. In addition, pursuant to terms of the new credit facility, we used a portion of the initial loan proceeds to repay all of the amounts we owed under the Loan Agreement to Oxford and Horizon, and the other lenders named therein. We intend to use the remainder of the initial loan proceeds (after deducting loan origination costs and other fees and expenses incurred in connection with the incurrence of the loan), plus any additional amounts that may be borrowed in the future, for general corporate purposes and working capital.

XML 25 R18.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies and basis of presentation (Policies)

6 Months Ended

Jun. 30, 2017

Summary of significant accounting policies and basis of presentation

Basis of presentation

Revenue Recognition

Revenue recognition

Inventory

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Our inventory consists of only finished goods.

Foreign currency translation

Use of estimates

Net loss per share

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of June 30, 2017 and 2016, as they would be anti-dilutive:


	Six Months Ended
	June 30,
	2017		2016
Warrants		7,428,571		—
Stock options issued and outstanding		6,139,647		3,293,341
Unvested restricted stock units		222,000		170,000

Recent accounting pronouncements

XML 26 R19.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies and basis of presentation (Tables)

6 Months Ended

Jun. 30, 2017

Summary of significant accounting policies and basis of presentation

Schedule of potentially dilutive securities excluded from computations of diluted weighted average shares outstanding


	Six Months Ended
	June 30,
	2017		2016
Warrants		7,428,571		—
Stock options issued and outstanding		6,139,647		3,293,341
Unvested restricted stock units		222,000		170,000

XML 27 R20.htm IDEA: XBRL DOCUMENT

Revenue recognition (Tables)

6 Months Ended

Jun. 30, 2017

Revenue recognition

Summary of product revenue allowance and reserve categories

The following table summarizes activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2017 (in thousands):



				Co-pay
		Trade		assistance		Government
		discount		program		rebates		Total
Balance at December 31, 2016	$	—	$	—	$	—	$	—
Provision related to current period sales		72		42		159		273
Adjustment related to prior period sales		—		—		—		—
Credit or payments made during the period		(72)		(35)		—		(107)
Balance at June 30, 2017	$	—	$	7	$	159	$	166

XML 28 R21.htm IDEA: XBRL DOCUMENT

Fair value measurement (Tables)

6 Months Ended

Jun. 30, 2017

Fair value measurement

Schedule of fair value of financial assets by level

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):


	As of June 30, 2017
	Level I		Level II		Level III		Total
Cash equivalents		33,579		—		—		33,579
Total assets	$	33,579	$	—	$	—	$	33,579
Warrant liabilities		—		—		41,237		41,237
Total liabilities	$	—	$	—	$	41,237	$	41,237


	As of December 31, 2016
	Level I		Level II		Level III		Total
Warrant liabilities		—		—		11,090		11,090
Total liabilities	$	—	$	—	$	11,090	$	11,090

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 29 R22.htm IDEA: XBRL DOCUMENT

Intangible assets and goodwill (Tables)

6 Months Ended

Jun. 30, 2017

Intangible assets and goodwill

Schedule of gross carrying amount of in process research and development and goodwill

The gross carrying amount of in‑process research and development, acquired developed product rights and goodwill is as follows (in thousands):


	As of June 30, 2017
	Beginning of Period		Additions		Amortization		End of Period
IPR&D	$	20,723	$	—	$	—	$	20,723
Acquired product rights		40,177		—		(2,511)		37,666
Goodwill		7,256		—		—		7,256
Total	$	68,156	$	—	$	(2,511)	$	65,645


	As of December 31, 2016
	Beginning of Period		Additions		Impairment		End of Period
IPR&D	$	36,551	$	—	$	(15,828)	$	20,723
Acquired product rights		—		40,177		—		40,177
Goodwill		7,256		—		—		7,256
Total	$	43,807	$	40,177	$	(15,828)	$	68,156

XML 30 R23.htm IDEA: XBRL DOCUMENT

Accrued liabilities (Tables)

6 Months Ended

Jun. 30, 2017

Accrued liabilities

Schedule of accrued liabilities

Accrued liabilities consist of the following (in thousands):


	June 30,		December 31,
	2017		2016
Consulting and professional fees	$	2,573	$	1,110
Accrued payable due Taro Pharmaceuticals Industries Ltd.		—		7,500
Accrued interest		430		—
Supply agreement - current portion		2,574		4,207
Employee compensation		1,351		1,554
Other		30		497
Total accrued liabilities	$	6,958	$	14,868

XML 31 R24.htm IDEA: XBRL DOCUMENT

Long Term Debt (Tables)

6 Months Ended

Jun. 30, 2017

Debt Disclosure

Future principal payments

Future principal payments due under the Loan Agreement are as follows (in thousands):


	Principal
	Payments

2017	$	—
2018		4,000
2019		8,000
2020		8,000
Total future payments	$	20,000

XML 32 R25.htm IDEA: XBRL DOCUMENT

Commitments and contingencies (Tables)

6 Months Ended

Jun. 30, 2017

Commitments and contingencies

Schedule of future minimum commitments under facility operating leases

As of June 30, 2017, future minimum commitments under facility operating leases were as follows (in thousands):


	Operating
	leases

2017	$	159
2018		319
2019		184
Total minimum lease payments	$	662

XML 33 R26.htm IDEA: XBRL DOCUMENT

Stock-based compensation (Tables)

6 Months Ended

Jun. 30, 2017

Stock-based compensation

Schedule of summary of outstanding stock options activity


	Options Outstanding
				Weighted-
				Average
		Weighted-		Remaining
		Average		Contractual
	Number of	Exercise		Term	Aggregate
	Shares	Price		(Years)	Intrinsic Value
					(in thousands)
Outstanding—January 1, 2017	3,249,784	$	11.00	6.89	$	—
Granted	2,943,200	$	3.44
Forfeited and cancelled	(53,337)	$	8.28
Exercised	—		—
Outstanding—June 30, 2017	6,139,647	$	7.40	8.02	$	14,417
Vested and exercisable—June 30, 2017	1,758,858	$	10.63	5.68	$	1,924

Schedule of stock-based compensation

We recognized stock‑based compensation expense for employees and directors for stock options and RSUs in the accompanying unaudited consolidated statements of operations as follows (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016
Research and development	$	281	$	(87)	$	498	$	196
General and administrative		1,082		1,177		2,035		2,222
Total stock-based compensation	$	1,363	$	1,090	$	2,533	$	2,418

Schedule of assumptions for estimating fair value of stock option awards


	Six Months Ended
	June 30,
	2017	2016
Expected term (in years)	5.95	5.87
Risk-free interest rate	1.78% - 2.26%	1.3% - 1.6%
Expected volatility	78.2% - 81.8%	78.1% - 83.6%
Dividend rate	—%	—%

Schedule of summary of unvested RSUs


		Number of
		Shares
Unvested—January 1, 2017		184,000
Granted		40,000
Forfeited		(2,000)
Vested		—
Unvested—June 30, 2017		222,000

XML 34 R27.htm IDEA: XBRL DOCUMENT

Organization - Products (Details)	Jun. 30, 2017 product
Organization
Number of clinical-stage product candidates	2

XML 35 R28.htm IDEA: XBRL DOCUMENT

Organization - Liquidity (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 14, 2017	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Liquidity
Cash		$ 33,864	$ 66,837	$ 33,884	$ 51,623
Subsequent event
Liquidity
Issuance of shares	$ 3,000
Price per share (in dollars per share)	$ 6.98
Subsequent event \| 2017 Credit Facility
Liquidity
Maximum borrowing capacity	$ 50,000
Proceeds from long-term debt	40,000
Additional borrowing capacity on achievement of milestones	$ 10,000

XML 36 R29.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies and basis of presentation - Antidilutive securities (Details) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Warrants
Net loss per share
Anti-dilutive shares of common stock (in shares)	7,428,571
Stock options
Net loss per share
Anti-dilutive shares of common stock (in shares)	6,139,647	3,293,341
RSUs
Net loss per share
Anti-dilutive shares of common stock (in shares)	222,000	170,000

XML 37 R30.htm IDEA: XBRL DOCUMENT

Revenue recognition - General (Details)	6 Months Ended
Revenue recognition - General (Details)	Jun. 30, 2017 pharmacy
Revenue recognition
Number of specialty pharmacy providers	1

XML 38 R31.htm IDEA: XBRL DOCUMENT

Revenue recognition - Allowance and Reserve (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($)
Reserves for Variable Consideration
Reserve for returns	$ 0
Percentage of patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap for which manufacturers of pharmaceutical products are responsible	50.00%
Maximum period for which patients may receive free product under Temporary Supply Program	60 days
Maximum period for which patients may receive free product under Patient Assistance Program	12 months
Product Revenue Allowance and Reserve
Product revenue allowance and reserves
Provision related to current period sales	$ 273
Credit or payments made during the period	(107)
Balance at end of period	166
Product Revenue Allowance And Reserve, Trade discount
Product revenue allowance and reserves
Provision related to current period sales	72
Credit or payments made during the period	(72)
Product Revenue Allowance and Reserve, Co-pay assistance program
Product revenue allowance and reserves
Provision related to current period sales	42
Credit or payments made during the period	(35)
Balance at end of period	7
Product Revenue Allowance and Reserve, Government rebates
Product revenue allowance and reserves
Provision related to current period sales	159
Balance at end of period	$ 159

XML 39 R32.htm IDEA: XBRL DOCUMENT

Fair value measurement (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Liabilities
Warrant liabilities	$ 41,237	$ 11,090
Recurring
Assets
Cash equivalents	33,579
Total Assets	33,579
Liabilities
Warrant liabilities	41,237	11,090
Total liabilities	41,237	11,090
Recurring \| Level I
Assets
Cash equivalents	33,579
Total Assets	33,579
Recurring \| Level III
Liabilities
Warrant liabilities	41,237	11,090
Total liabilities	$ 41,237	$ 11,090

XML 40 R33.htm IDEA: XBRL DOCUMENT

Intangible assets and goodwill - Components (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
In-process research and development and Goodwill
Acquired product rights, Amortization	$ (1,255)	$ (2,511)
Goodwill, Beginning of Period		7,256	$ 7,256
Goodwill, End of Period	7,256	7,256	7,256
Total, Beginning of Period		68,156	43,807
Total, Additions			40,177
Total, Amortization	(1,255)	(2,511)
Total Impairment			(15,828)
Total, End of Period	65,645	65,645	68,156
Acquired product rights
In-process research and development and Goodwill
Acquired product rights, Beginning of Period		40,177
Acquired product rights, Additions			40,177
Acquired product rights, Amortization		(2,511)
Acquired product rights, End of Period	37,666	37,666	40,177
Total, Amortization		(2,511)
IPR&D
In-process research and development and Goodwill
IPR&D, Beginning of Period		20,723	36,551
IPR&D, Impairment			(15,828)
IPR&D, End of Period	$ 20,723	$ 20,723	$ 20,723

XML 41 R34.htm IDEA: XBRL DOCUMENT

Intangible assets and goodwill - Asset purchase (Details) $ in Thousands	1 Months Ended		3 Months Ended	6 Months Ended	12 Months Ended
	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) payment	Jun. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2016 USD ($) payment	Dec. 31, 2016 item	Dec. 31, 2016 USD ($)
In-process research and development and Goodwill
Amortization of intangible asset			$ 1,255	$ 2,511
Acquired product rights
In-process research and development and Goodwill
Acquired product rights			$ 37,666	37,666			$ 40,177
Transaction costs							2,400
Estimated life		8 years
Amortization of intangible asset				$ 2,511
IPR&D
In-process research and development and Goodwill
IPR&D, Impairment					$ (15,828)
Asset Purchase Agreement \| Keveyis \| Taro \| Acquired product rights
In-process research and development and Goodwill
Number of installment payments		2			2	2
Installment payment	$ 7,500	$ 1,000
Supply Agreement \| Keveyis \| Taro \| Acquired product rights
In-process research and development and Goodwill
Acquired product rights							$ 29,300

XML 42 R35.htm IDEA: XBRL DOCUMENT

Accrued liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accrued liabilities
Consulting and professional fees	$ 2,573	$ 1,110
Accrued payable due Taro Pharmaceuticals Industries Ltd		7,500
Accrued interest	430
Supply agreement - current portion	2,574	4,207
Employee compensation	1,351	1,554
Other	30	497
Total accrued liabilities	$ 6,958	$ 14,868

XML 43 R36.htm IDEA: XBRL DOCUMENT

Long Term Debt - Agreements (Details)			6 Months Ended
Long Term Debt - Agreements (Details)	Mar. 31, 2017 USD ($)	Dec. 28, 2016 USD ($) item $ / shares shares	Jun. 30, 2017 USD ($)
Loan agreement
Payment for amendment of long-term debt			$ 150,000
2016 Credit Facility
Loan agreement
Maximum borrowing capacity		$ 40,000,000
Line of credit proceeds		$ 20,000,000
Number of additional tranches \| item		2
Credit facility term		48 months
Interest-only payment period		18 months
Amortization period		30 months
Final payment fee (as a percent)		8.00%
Fixed interest rate (as a percent)		8.22%
Variable interest rate (as a percent)		0.53%
Debt discounts		$ 1,300,000
Debt issuance costs		300,000
Payment for amendment of long-term debt	$ 150,000
Additional debt discount	150,000
2016 Credit Facility \| Minimum
Loan agreement
Amount of cash collateral	100,000
2016 Credit Facility \| Maximum
Loan agreement
Amount of cash collateral	$ 250,000
2016 Credit Facility-Tranche One
Loan agreement
Additional borrowing capacity on achievement of milestones		10,000,000
2016 Credit Facility-Tranche Two
Loan agreement
Additional borrowing capacity on achievement of milestones		$ 10,000,000
Amortization period		24 months
Interest payment only extension period		6 months
Warrants in connection with 2016 loan agreement \| 2016 Credit Facility
Loan agreement
Securities that warrants may purchase (in shares) \| shares		428,571
Warrant exercise price (in dollars per share) \| $ / shares		$ 2.45
Warrant expiration period		10 years

XML 44 R37.htm IDEA: XBRL DOCUMENT

Long Term Debt - Future principal payments (Details) $ in Thousands	Jun. 30, 2017 USD ($)
Future principal payments
2018	$ 4,000
2019	8,000
2020	8,000
Total future payments	$ 20,000

XML 45 R38.htm IDEA: XBRL DOCUMENT

Long Term Debt - Prepayment (Details) - 2016 Credit Facility $ in Millions	Jul. 14, 2017 USD ($)
Debt
Prepayment fee	$ 0.8
Interest charges	$ 1.6

XML 46 R39.htm IDEA: XBRL DOCUMENT

Commitments and contingencies - Lease (Details)	1 Months Ended	6 Months Ended
Commitments and contingencies - Lease (Details)	Mar. 31, 2015 ft²	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)
Future minimum commitments under facility operating leases
2017		$ 159,000
2018		319,000
2019		184,000
Total minimum lease payments		662,000
Rent expense		$ 152,000	$ 138,000
Building lease, March 2015
Lease
Lease term	52 months
Amount of space leased (in square feet) \| ft²	14,743

XML 47 R40.htm IDEA: XBRL DOCUMENT

Commitments and contingencies - Commitments to Taro (Details) - Acquired product rights - Taro - Keveyis $ in Millions	1 Months Ended
	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) payment	Dec. 31, 2016 item	Dec. 31, 2016 USD ($)
Asset Purchase Agreement
Other Commitments
Number of installment payments		2	2
Installment payment	$ 7.5	$ 1.0
Potential milestone payments				$ 7.5
Supply Agreement
Other Commitments
Minimum amount of purchases obligated				$ 29.0
Purchase obligation period		6 years

XML 48 R41.htm IDEA: XBRL DOCUMENT

Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Components of income tax (benefit) provision
Income tax expense	$ (92)	$ (871)	$ 1,502	$ (926)

XML 49 R42.htm IDEA: XBRL DOCUMENT

Stock-based compensation - General (Details)	Jun. 30, 2017 shares
Inducement Plan
Stock-based compensation
Number of shares available for issuance	89,850
2015 Plan
Stock-based compensation
Number of shares available for issuance	428,814
Non-Employee Director Plan
Stock-based compensation
Number of shares available for issuance	792

XML 50 R43.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Stock options (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Summary of outstanding stock options
Outstanding at beginning of period (in shares)	3,249,784
Granted (in shares)	2,943,200
Forfeited and cancelled (in shares)	(53,337)
Outstanding at end of period (in shares)	6,139,647	3,249,784
Vested and exercisable at end of period (in shares)	1,758,858
Weighted-Average Exercise Price
Granted (in dollars per share)	$ 3.44
Forfeited and cancelled (in dollars per share)	8.28
Outstanding (in dollars per share)	7.40	$ 11.00
Vested and exercisable at end of period (in dollars per share)	$ 10.63
Additional Disclosures - Options
Weighted Average Remaining Contractual Term, Outstanding	8 years 7 days	6 years 10 months 21 days
Weighted Average Remaining Contractual Term, Vested and exercisable	5 years 8 months 5 days
Aggregate Intrinsic Value, Outstanding (in dollars)	$ 14,417
Aggregate Intrinsic Value, Vested and exercisable at end of the period (in dollars)	$ 1,924

XML 51 R44.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Options outstanding (Details) - $ / shares	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Stock options
Options outstanding (in shares)	6,139,647	3,249,784
Options outstanding, weighted-average exercise price (in dollars per share)	$ 7.40	$ 11.00
Vesting subject to acceleration
Stock options
Options outstanding (in shares)	88,908
Options outstanding, weighted-average exercise price (in dollars per share)	$ 18.80
Vesting subject to acceleration \| Grantee, Two
Stock options
Share price threshold	31.46
Vesting based on market appreciation event \| Grantee, Four
Stock options
Share price threshold	30.14
Vesting based on market appreciation event \| Grantee, Five
Stock options
Share price threshold	$ 33.66
Vesting based on market appreciation event \| Vesting at market appreciation event
Stock options
Options outstanding (in shares)	97,652
Consecutive trading days threshold	20 days
Vesting based on market appreciation event \| Vesting at one year anniversary of market appreciation event
Stock options
Options outstanding (in shares)	97,652
Vesting period following event	1 year
Consecutive trading days threshold	20 days

XML 52 R45.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Stock-based compensation expense
Total stock-based compensation	$ 1,363	$ 1,090	$ 2,533	$ 2,418
Employee and directors stock options
Stock-based compensation expense
Total unrecognized compensation expense	11,300		$ 11,300
Estimated weighted average period over which expense is expected to be recognized			2 years 11 months 1 day
Research and development
Stock-based compensation expense
Total stock-based compensation	281	(87)	$ 498	196
General and administration expense
Stock-based compensation expense
Total stock-based compensation	$ 1,082	$ 1,177	$ 2,035	$ 2,222

XML 53 R46.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Fair value assumptions (Details)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Fair value assumptions
Expected term (in years)	5 years 11 months 12 days	5 years 10 months 13 days
Minimum Risk-free interest rate (as a percent)	1.78%	1.30%
Maximum Risk-free interest rate (as a percent)	2.26%	1.60%
Minimum Expected volatility (as a percent)	78.20%	78.10%
Maximum Expected volatility (as a percent)	81.80%	83.60%

XML 54 R47.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Restricted stock units (Details) - USD ($)		3 Months Ended		6 Months Ended
	Feb. 26, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Stock-based compensation
Stock-based compensation		$ 1,363,000	$ 1,090,000	$ 2,533,000	$ 2,418,000
RSUs
Stock-based compensation
Vesting period	2 years
Number of shares issued for each stock award vested	1
Stock-based compensation		98,000	$ 78,000	185,000	$ 112,000
Total unrecognized compensation expense		$ 400,000		$ 400,000
Estimated weighted average period over which expense is expected to be recognized				1 year 2 months 12 days
Summary of unvested RSUs
Unvested - Beginning of period (in shares)				184,000
Granted (in shares)				40,000
Forfeited (in shares)				(2,000)
Unvested - End of period (in shares)		222,000		222,000

XML 55 R48.htm IDEA: XBRL DOCUMENT

Subsequent events (Details) - Subsequent event $ / shares in Units, $ in Millions	Jul. 14, 2017 USD ($) $ / shares shares
Subsequent events
Issuance of shares	$ 3
Price per share (in dollars per share) \| $ / shares	$ 6.98
Warrants in connection with 2017 loan agreement
Subsequent events
Warrant term	7 years
Securities that warrants may purchase (in shares) \| shares	394,289
Warrant exercise price (in dollars per share) \| $ / shares	$ 7.37
2017 Credit Facility
Subsequent events
Maximum borrowing capacity	$ 50
Proceeds from long-term debt	40
Additional borrowing capacity on achievement of milestones	$ 10
Loan agreement term	6 years
Interest only payment term	3 years
Extension of interest only payment term upon achievement of milestones	6 years

EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 98 214 1 false 44 0 false 9 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.strongbridgebio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://www.strongbridgebio.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.strongbridgebio.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.strongbridgebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00300 - Statement - Consolidated Statement of Shareholders' Equity Sheet http://www.strongbridgebio.com/role/StatementConsolidatedStatementOfShareholdersEquity Consolidated Statement of Shareholders' Equity Statements 5 false false R6.htm 00400 - Statement - Consolidated Statements of Cash Flow Sheet http://www.strongbridgebio.com/role/StatementConsolidatedStatementsOfCashFlow Consolidated Statements of Cash Flow Statements 6 false false R7.htm 10101 - Disclosure - Organization Sheet http://www.strongbridgebio.com/role/DisclosureOrganization Organization Notes 7 false false R8.htm 10201 - Disclosure - Summary of significant accounting policies and basis of presentation Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation Summary of significant accounting policies and basis of presentation Notes 8 false false R9.htm 10301 - Disclosure - Revenue recognition Sheet http://www.strongbridgebio.com/role/DisclosureRevenueRecognition Revenue recognition Notes 9 false false R10.htm 10401 - Disclosure - Fair value measurement Sheet http://www.strongbridgebio.com/role/DisclosureFairValueMeasurement Fair value measurement Notes 10 false false R11.htm 10501 - Disclosure - Intangible assets and goodwill Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwill Intangible assets and goodwill Notes 11 false false R12.htm 10601 - Disclosure - Accrued liabilities Sheet http://www.strongbridgebio.com/role/DisclosureAccruedLiabilities Accrued liabilities Notes 12 false false R13.htm 10701 - Disclosure - Long Term Debt Sheet http://www.strongbridgebio.com/role/DisclosureLongTermDebt Long Term Debt Notes 13 false false R14.htm 10801 - Disclosure - Commitments and contingencies Sheet http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingencies Commitments and contingencies Notes 14 false false R15.htm 10901 - Disclosure - Income taxes Sheet http://www.strongbridgebio.com/role/DisclosureIncomeTaxes Income taxes Notes 15 false false R16.htm 11001 - Disclosure - Stock-based compensation Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensation Stock-based compensation Notes 16 false false R17.htm 11101 - Disclosure - Subsequent events Sheet http://www.strongbridgebio.com/role/DisclosureSubsequentEvents Subsequent events Notes 17 false false R18.htm 20202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies Summary of significant accounting policies and basis of presentation (Policies) Policies 18 false false R19.htm 30203 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables Summary of significant accounting policies and basis of presentation (Tables) Tables http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 19 false false R20.htm 30303 - Disclosure - Revenue recognition (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureRevenueRecognitionTables Revenue recognition (Tables) Tables http://www.strongbridgebio.com/role/DisclosureRevenueRecognition 20 false false R21.htm 30403 - Disclosure - Fair value measurement (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureFairValueMeasurementTables Fair value measurement (Tables) Tables http://www.strongbridgebio.com/role/DisclosureFairValueMeasurement 21 false false R22.htm 30503 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible assets and goodwill (Tables) Tables http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwill 22 false false R23.htm 30603 - Disclosure - Accrued liabilities (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureAccruedLiabilitiesTables Accrued liabilities (Tables) Tables http://www.strongbridgebio.com/role/DisclosureAccruedLiabilities 23 false false R24.htm 30703 - Disclosure - Long Term Debt (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureLongTermDebtTables Long Term Debt (Tables) Tables http://www.strongbridgebio.com/role/DisclosureLongTermDebt 24 false false R25.htm 30803 - Disclosure - Commitments and contingencies (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and contingencies (Tables) Tables http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingencies 25 false false R26.htm 31003 - Disclosure - Stock-based compensation (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationTables Stock-based compensation (Tables) Tables http://www.strongbridgebio.com/role/DisclosureStockBasedCompensation 26 false false R27.htm 40101 - Disclosure - Organization - Products (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrganizationProductsDetails Organization - Products (Details) Details 27 false false R28.htm 40102 - Disclosure - Organization - Liquidity (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrganizationLiquidityDetails Organization - Liquidity (Details) Details 28 false false R29.htm 40201 - Disclosure - Summary of significant accounting policies and basis of presentation - Antidilutive securities (Details) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAntidilutiveSecuritiesDetails Summary of significant accounting policies and basis of presentation - Antidilutive securities (Details) Details 29 false false R30.htm 40301 - Disclosure - Revenue recognition - General (Details) Sheet http://www.strongbridgebio.com/role/DisclosureRevenueRecognitionGeneralDetails Revenue recognition - General (Details) Details 30 false false R31.htm 40302 - Disclosure - Revenue recognition - Allowance and Reserve (Details) Sheet http://www.strongbridgebio.com/role/DisclosureRevenueRecognitionAllowanceAndReserveDetails Revenue recognition - Allowance and Reserve (Details) Details 31 false false R32.htm 40401 - Disclosure - Fair value measurement (Details) Sheet http://www.strongbridgebio.com/role/DisclosureFairValueMeasurementDetails Fair value measurement (Details) Details http://www.strongbridgebio.com/role/DisclosureFairValueMeasurementTables 32 false false R33.htm 40501 - Disclosure - Intangible assets and goodwill - Components (Details) Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails Intangible assets and goodwill - Components (Details) Details 33 false false R34.htm 40502 - Disclosure - Intangible assets and goodwill - Asset purchase (Details) Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwillAssetPurchaseDetails Intangible assets and goodwill - Asset purchase (Details) Details 34 false false R35.htm 40601 - Disclosure - Accrued liabilities (Details) Sheet http://www.strongbridgebio.com/role/DisclosureAccruedLiabilitiesDetails Accrued liabilities (Details) Details http://www.strongbridgebio.com/role/DisclosureAccruedLiabilitiesTables 35 false false R36.htm 40701 - Disclosure - Long Term Debt - Agreements (Details) Sheet http://www.strongbridgebio.com/role/DisclosureLongTermDebtAgreementsDetails Long Term Debt - Agreements (Details) Details 36 false false R37.htm 40702 - Disclosure - Long Term Debt - Future principal payments (Details) Sheet http://www.strongbridgebio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails Long Term Debt - Future principal payments (Details) Details 37 false false R38.htm 40703 - Disclosure - Long Term Debt - Prepayment (Details) Sheet http://www.strongbridgebio.com/role/DisclosureLongTermDebtPrepaymentDetails Long Term Debt - Prepayment (Details) Details 38 false false R39.htm 40801 - Disclosure - Commitments and contingencies - Lease (Details) Sheet http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingenciesLeaseDetails Commitments and contingencies - Lease (Details) Details 39 false false R40.htm 40802 - Disclosure - Commitments and contingencies - Commitments to Taro (Details) Sheet http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingenciesCommitmentsToTaroDetails Commitments and contingencies - Commitments to Taro (Details) Details 40 false false R41.htm 40901 - Disclosure - Income taxes (Details) Sheet http://www.strongbridgebio.com/role/DisclosureIncomeTaxesDetails Income taxes (Details) Details http://www.strongbridgebio.com/role/DisclosureIncomeTaxes 41 false false R42.htm 41001 - Disclosure - Stock-based compensation - General (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationGeneralDetails Stock-based compensation - General (Details) Details 42 false false R43.htm 41002 - Disclosure - Stock-based compensation - Stock options (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationStockOptionsDetails Stock-based compensation - Stock options (Details) Details 43 false false R44.htm 41003 - Disclosure - Stock-based compensation - Options outstanding (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails Stock-based compensation - Options outstanding (Details) Details 44 false false R45.htm 41004 - Disclosure - Stock-based compensation - Stock-based compensation expense (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-based compensation - Stock-based compensation expense (Details) Details 45 false false R46.htm 41005 - Disclosure - Stock-based compensation - Fair value assumptions (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationFairValueAssumptionsDetails Stock-based compensation - Fair value assumptions (Details) Details 46 false false R47.htm 41006 - Disclosure - Stock-based compensation - Restricted stock units (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails Stock-based compensation - Restricted stock units (Details) Details 47 false false R48.htm 41101 - Disclosure - Subsequent events (Details) Sheet http://www.strongbridgebio.com/role/DisclosureSubsequentEventsDetails Subsequent events (Details) Details http://www.strongbridgebio.com/role/DisclosureSubsequentEvents 48 false false All Reports Book All Reports sbbp-20170630.xml sbbp-20170630.xsd sbbp-20170630_cal.xml sbbp-20170630_def.xml sbbp-20170630_lab.xml sbbp-20170630_pre.xml true true ZIP 62 0001558370-17-006055-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-17-006055-xbrl.zip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�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µ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end